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ABSTRACT 
Karri Utriainen.  
Sleep-time predictors of cardiovascular complications in surgical peripheral arterial disease. 
  
University of Turku, Faculty of Medicine, Internal Medicine, Doctoral Programme in Clinical 
Research, Sleep Research Unit; Division of Medicine, Heart Centre, Division of Perioperative Services, 
Intensive Care Medicine and Pain Management, Turku University Hospital, Finland. 
Annales Universitatis Turkuensis, Ser. D, Medica – Odontologica; Painola Oy, Kaarina, Finland, 2019 
 
Patients with peripheral arterial disease (PAD) undergoing surgical revascularisation are in high risk of 
postoperative cardiovascular complications and death, due to advancing age and multiple co-
morbidities in the population. In addition, PAD needing surgery represents a severe form of systemic 
atherosclerosis but the exact underlying pathophysiology of acute myocardial infarction (AMI) in these 
patients is unclear and predicting outcome especially in the long-term is challenging. 
Obstructive sleep apnoea (OSA) is increasingly common in the general population and 
independently associated with various manifestations of cardiovascular disease or their risk factors; 
OSA is highly prevalent in patients with coronary artery disease (CAD), stroke, hypertension and 
diabetes. To expand this knowledge, we determined the prevalence and severity (in terms of the apnoea-
hypopnoea index, AHI) of OSA in surgical PAD as well as its impact on the incidence of major adverse 
cardiovascular and cerebrovascular events (MACCE) in this patient group.  
Heart rate variability (HRV) reflects fluctuations in sympathetic and parasympathetic activation 
responsible for neurocirculatory control in various physiological and pathophysiological situations. 
Depressed HRV is associated with increased cardiovascular morbidity and mortality following AMI 
and major surgery. In this study, the alterations of nocturnal HRV and their association with the severity 
of OSA and incidence of MACCE in patients with PAD was assessed, including the fractal correlation 
properties of HRV. HRV in a control group of 15 healthy subjects was also examined. 
Patients scheduled for sub-inguinal vascular surgery (n=84, age 67±9 years) underwent 
polysomnography and HRV analyses. OSA was detected in 86% of patients and in 56% it was moderate 
or severe. Age, male gender, depressed left ventricular function and decreasing high density 
lipoprotein/cholesterol ratio (HDL/Chol) predicted the presence and severity of OSA. The latter two 
remained significant after adjusting for age and gender. OSA with AHI ≥20/hour, used as a cut-off in 
the outcome analyses, predicted a higher risk of MACCE (p=0.001) along with pre-existing CAD 
(p=0.001), decreasing HDL/Chol (p=0.048) and <4 years history of PAD (p=0.018).   
HRV was altered in patients with PAD when compared to controls but the time domain measures 
were mostly unchanged. In the frequency domain, low frequency power was generally lower, high 
frequency power was mostly higher and fractal correlation was consistently lower. Very low frequency 
power was increased the most in patients with AHI 10-20/hour when compared to <10/hour while those 
with AHI ≥20/hour had lower fractal correlation in the morning. Patients suffering a MACCE had lower 
high frequency power during S3-4 and rapid eye movement sleep. 
In conclusion, OSA is associated with worsening atherosclerosis and predicts MACCE after 
vascular surgery. HRV alterations, although associated with PAD, have limited predictive value.  
 
Keywords: atherosclerosis, peripheral arterial disease, sleep apnoea, heart rate variability 
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Perifeeristä valtimotautia sairastavilla potilailla on suuri leikkauksenjälkeisten sydänkomplikaatioiden riski 
johtuen yhä iäkkäämmästä väestöstä sekä lukuisista rinnakkaissairauksista. Lisäksi perifeerinen valtimotauti 
merkitsee vaikea-asteista yleistynyttä ateroskleroosia, mutta sydäninfarktin tarkka syntymekanismi näillä 
potilailla on epäselvä ja erityisesti pitkän aikavälin ennusteen arviointi on haastavaa.   
 Obstruktiivinen uniapnea yleistyy väestössä ja sillä on itsenäinen yhteys useisiin sydän- ja 
verisuonisairauksiin ja niiden riskitekijöihin; uniapnea on erittäin yleinen sepelvaltimotauti-, aivohalvaus-, 
verenpainetauti- ja diabetespotilailla. Tämän tietopohjan laajentamiseksi tässä tutkimuksessa määritettiin 
uniapnean esiintyvyys ja vaikeusaste (määrittäjänä apnea-hypopneaindeksi, AHI) vaikea-asteista yleistynyttä 
ateroskleroosia sairastavilla potilailla sekä sen vaikutus vakavien sydän- ja aivotapahtumien ilmaantuvuuteen. 
Sydämen sykevaihtelu kuvastaa autonomisen hermoston toiminnan muutoksia, jotka puolestaan 
vastaavat verenkierron säätelystä erilaisissa fysiologisissa ja patofysiologisissa tilanteissa. Alentunut 
sykevaihtelu on yhteydessä lisääntyneeseen kardiovaskulaariseen sairastuvuuteen ja kuolleisuuteen 
sairastetun sydäninfarktin tai suuren leikkauksen jälkeen. Tässä tutkimuksessa arvioitiin yöllisen sydämen 
sykevaihtelun muutosten yhteyttä uniapnean vaikeusasteeseen sekä vakavien sydän- ja aivotapahtumien 
ilmaantuvuuteen, mukaan lukien sykevaihtelun fraktaalikorrelaatio-ominaisuudet. Tutkimuksessa 
analysoitiin sykevaihtelu myös 15 terveen henkilön vertailuryhmältä.  
Nivustason alapuoliseen verisuonileikkaukseen meneville potilaille (n=84, ikä 67±9 vuotta) tehtiin 
unipolygrafia ja sykevaihteluanalyysi. Uniapnea todettiin 86 %:lla potilaista ja 56 %:lla se oli kohtalainen tai 
vaikea. Ikä, miessukupuoli, heikentynyt vasemman kammion toiminta ja alentunut HDL-kolesterolin suhde 
kokonaiskolesteroliin ennustivat uniapneaa ja sen vaikeutumista; 2 viimeksi mainittua säilyivät merkitsevinä 
ikä- ja sukupuolivakioinnin jälkeen. AHI ≥20/tunti, joka valittiin kynnysarvoksi päätetapahtuma-
analyyseihin, ennusti merkitsevästi vakavia sydän- ja aivotapahtumia (p=0.001). Muita merkitseviä tekijöitä 
olivat sepelvaltimotauti (p=0.001), alentunut HDL-suhde (p=0.048) ja lyhyt (alle 4 vuotta) perifeerisen 
valtimotaudin kesto ennen leikkaushoidon tarvetta (p=0.018). 
Sykevaihtelu oli muuttunut valtimotautipotilailla verrattuna kontrolleihin, mutta aikakenttäparametrit 
säilyivät lähes ennallaan. Pienitaajuuksinen sykevaihtelu oli yleisesti vähäisempää, suuritaajuuksinen 
enimmäkseen voimakkaampaa ja fraktaalikorrelaatio johdonmukaisesti heikompaa. Hyvin pienitaajuuksinen 
vaihtelu oli eniten lisääntynyt AHI 10-20/tunti -alaryhmässä verrattuna AHI <10/tunti -ryhmään, mutta AHI 
≥20/tunti -potilailla aamun fraktaalikorrelaatio oli heikompaa. Potilaiden, jotka saivat vakavia sydän- ja 
aivotapahtumia, suuritaajuusvaihtelu oli heikompaa syvän unen ja vilkeunen aikana. 
Johtopäätöksinä todetaan, että uniapnea on yhteydessä vaikeutuvaan valtimotautiin sekä ennustaa 
vakavia sydän- ja aivotapahtumia verisuonileikkauksen jälkeen sykevaihtelun muutosten ennustearvon 
ollessa tässä aineistossa hyvin rajallinen. 
Avainsanat: ateroskleroosi, perifeerinen valtimotauti, uniapnea, sykevaihtelu 
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1. INTRODUCTION  
Peripheral arterial disease (PAD) is a systemic manifestation of atherosclerosis 
despite that the clinical presentation is typically in the lower extremities. This is 
perceived to be true even when there are no clinical manifestations in other target 
organs, e.g. cerebrovascular or coronary artery disease (Hirsch et al. 2001). PAD 
requiring surgical treatment, in turn, represents a severe form of PAD, i.e. severe 
systemic atherosclerosis. Consequently, these patients have a high risk of 
postoperative cardiovascular complications (e.g. myocardial infarction, cardiac 
death), and their five-year mortality is approximately 30 % (Landesberg et al. 2003; 
Levy et al. 2011). To predict and prevent this risk, a variety of methods have been 
employed such as index scores, preoperative cardiac assessments and invasive 
coronary intervention (Halm et al. 1996; Fleisher et al. 2007; Poldermans et al. 
2007). However, the clinical value of these means of risk stratification is limited, 
partly because the underlying pathophysiology of the cardiac complications is 
incompletely understood, and predicting the risk of an individual patient to guide 
clinical decisions remains a challenge (Devereaux et al. 2005).  
Sleep-disordered breathing consists of both central and obstructive sleep apnoea 
(OSA) as well as overlapping forms. In this thesis, OSA is used when obstructive 
apnoea is the sole or predominant type. Symptomatic OSA syndrome affects 2-4 % 
of general population (Young et al. 1993) but the overall prevalence of OSA is much 
higher, up to 23-28 % (Young et al. 2002; Duran et al. 2001). The prevalence of OSA 
seems to increase in parallel with worsening cardiovascular disease; it is 30-40 % in 
coronary artery disease (Peker et al. 1999; Mooe et al. 2001) and 60-70 % in patients 
suffering a stroke (Wessendorf et al. 2000; Rola et al. 2007). The established risk 
factors of cardiovascular disease such as hypertension and insulin resistance also 
have a strong association with OSA (Nieto et al. 2000; Peppard et al. 2000). OSA 
carries a markedly increased risk of cardiovascular morbidity and mortality that may 
be reversible with continuous positive airway pressure (CPAP) treatment (Marin et 
al. 2005; Campos-Rodriguez et al. 2012). It has been estimated that the majority of 
patients with moderate-to-severe OSA are undiagnosed (Young et al. 1997). The 
recognition and management of pre-existing of OSA in general surgical population 
is also poor (Singh et al. 2013). Patients with PAD were not studied until recently 
(Pizarro et al. 2015; Schahab et al. 2017), and neither the prevalence of OSA in 
surgical PAD nor its effect on postoperative prognosis have been previously 
determined. 
Heart rate variability (HRV) reflects autonomic neurocirculatory regulation and 
depressed HRV is associated with postoperative myocardial infarction and death 
following major peripheral vascular surgery (Mamode et al. 2001; Filipovic et al. 
2003). Impaired HRV is especially detrimental in patients with coronary artery 
disease and is a stronger predictor of myocardial ischaemia and mortality than 
common clinical risk stratification methods (Tapanainen et al. 2002; Laitio et al. 
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2004). In PAD the behaviour of the various HRV parameters is less clear (Goernig 
et al. 2008; Leicht et al. 2011), but OSA seems to be associated with HRV alterations 
indicating increased sympathetic activation and worse prognosis (Narkiewicz et al 
1998; Dingli et al. 2003). While depressed nocturnal HRV promotes postoperative 
myocardial ischaemia following non-cardiac surgery (Laitio et al. 2004), HRV 
alterations during sleep in patients with surgical PAD and OSA and their impact on 
long-term morbidity and mortality have not been specifically studied.  
In this thesis, we investigated a carefully selected patient population undergoing sub-
inguinal vascular surgery to determine the prevalence of occult OSA in surgical PAD 
as well as its putative predictive value for perioperative cardiac complications and 
long-term postoperative outcome. The demographic and clinical features of OSA in 
severe PAD are determined and its possible aetiologies are contemplated. 
Characteristics of nocturnal HRV during different sleep stages are measured, and the 
predictive value of HRV for significant OSA and adverse postoperative outcome in 
this specific patient population is explored. 
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2. REVIEW OF THE LITERATURE 
2.1 Basic physiology of circulation and respiration  
Circulation is modified by complex neurohumoral feedback mechanisms that 
regulate circulatory adaptability and the function of the autonomic nervous system 
(ANS) is a major factor in the maintenance of cardiorespiratory homeostasis. The 
sympathetic branch of the ANS exerts powerful hemodynamic effects by increasing 
peripheral vasoconstriction, heart rate and myocardial contractility. Parasympathetic 
vagal activation buffers these changes to maintain hemodynamic balance and 
prevent sympathetic overdrive. (Barrett et al. 2010). Persistent sympathetic activity 
increases vascular tone, promoting arterial stiffness (Sun 2015).  
The chemoreceptors and baroreceptors form a complex system that regulates ANS 
activity. The chemoreceptors maintain balance of arterial gas tensions, mainly the 
partial pressures of oxygen (O2) and carbon dioxide (CO2). Peripheral 
chemoreceptors in the carotid body react primarily to hypoxia while central 
chemoreceptors are located in the brain stem and respond primarily to hypercapnia. 
Normally, hypercapnia exerts a more powerful excitatory effect on ventilation than 
hypoxia (Somers et al. 1989). Activation of the chemoreceptors increases 
sympathetic activity, heart rate and respiratory drive which are buffered by input 
from the baroreceptors of the aortic arch and pulmonary afferent nerves of the 
thoracic wall (Barrett et al. 2010). Disturbance of this protective mechanism may 
cause sympathetic overdrive, predisposing to acute myocardial infarction (AMI), 
arrhythmias and stroke. 
Vascular endothelium plays an important role in the regulation of circulation by 
promoting vasodilatation via release of nitric oxide. The endothelium also produces 
numerous other vasoactive agents and inflammatory mediators that control 
vasomotor tone and blood coagulation (Barrett et al. 2010). Therefore, a healthy 
endothelium is crucial in the maintenance of normal circulation. 
2.2 Pathogenesis and natural course of atherosclerosis 
2.2.1 Pathogenesis and pathophysiology, basic concepts  
Several risk factors predispose to the development of atherosclerotic vascular 
damage, starting at an early age (Stary 2000). Positive family history of 
cardiovascular disease is a major indicator of increased risk in which case primary 
prevention by lifestyle changes and management of other modifiable factors is 
especially important (Pandey et al. 2013).  Excess dietary intake of saturated fatty 
acids increases concentration of low-density lipoproteins (LDL), promoting the 
accumulation of cholesterol in the arterial wall whereas high-density lipoproteins 
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(HDL) are important in preventing atherosclerosis (Expert Dyslipidemia Panel 2013; 
Pekkanen et al. 1990).  Mechanisms include aggravation of oxidative stress, 
promotion of endothelial dysfunction and thrombosis (Barter 2011). Numerous other 
dietary factors along with sedentary lifestyle and lack of physical activity are also 
detrimental (Mozaffarian 2016; Tikkanen et al. 2018), as well as smoking (Fowkes 
et al. 1992). Ageing increases arterial stiffness, promoting hypertension and 
decreasing overall cardiovascular adaptability (Sun 2015).  Sustained arterial 
hypertension is a well-established risk factor as well as diabetes mellitus and insulin 
resistance (Fowkes et al. 1992; Ishizaka et al. 2003). Furthermore, dyslipidemia, 
hypertension and insulin resistance are frequently clustered in patients presenting 
with obesity, constituting the metabolic syndrome that is associated with 
asymptomatic atherosclerotic changes before the onset of clinical disease (Hunt et 
al. 2003; Grundy et al. 2005). Importantly, endothelium is prone to damage due to 
free oxygen radicals; oxidative stress promotes systemic inflammation, oxygenation 
of lipoproteins and thrombocyte aggregation (Li et al. 2014; Förstermann et al. 2017) 
and progressive loss of endothelial vasodilatory function begins in the early stage of 
atherosclerosis (Zeiher et al. 1991). 
2.2.2 Advanced systemic atherosclerosis and PAD 
2.2.2.1 Pathogenesis and epidemiology of PAD 
Atherosclerosis in the iliac or lower extremity arteries commonly manifests in 
intermittent claudication or critical limb ischaemia resulting in peripheral gangrenes. 
PAD is commonly referred to as advanced systemic atherosclerosis although such 
patients do not necessarily have clinical coronary artery or cerebrovascular disease 
(Hirsch et al. 2001). More specifically, the term lower extremity arterial disease 
(LEAD) is sometimes used to address vascular disease in leg arteries. All metabolic 
risk factors of atherosclerosis are also associated with PAD (Fowkes et al. 1992) and 
markers of vascular inflammation have also been shown to be associated with 
progression of peripheral atherosclerosis (Tzoulaki et al. 2005).  In patients with 
diabetes mellitus, PAD or LEAD is especially common and is closely connected with 
a high prevalence of dyslipidemia and hypertension (MacGregor et al. 1999) but the 
presence and pre-existing complications of diabetes seem to be essential (Wang et 
al. 2007). Of other risk factors, smoking is even more important than in coronary 
artery disease and its harmful effect increases with the daily number of cigarettes 
smoked (Fowkes et al. 1992; Criqui 2001). 
The state of lower limb peripheral circulation can be measured with the ankle-
brachial index (ABI), i.e. the ratio of blood pressures measured from the ankle and 
arm. The method is recommended as a non-invasive and inexpensive means for 
diagnosis (Aboyans et al. 2018). The sensitivity and specificity of the method is high 
for an angiographically diagnosed stenosis (Criqui et al. 1996). Normally this ratio 
is 1.0 or more and the commonly used cut-off level for PAD is 0.9 or below (Aboyans 
et al. 2012); intermittent claudication may or may not be present with mild-to-
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moderately decreased ABI while ABI <0.4 indicates critical ischaemia (Aboyans et 
al. 2018). In diabetic patients, the index may be abnormally high due to 
mediasclerosis (Aboyans et al. 2012). Toe pressure measurements can be used as a 
substitute for ABI in diabetic patients (Sahli et al. 2004; Bhamidipaty et al. 2015). A 
variety of classifications based on symptoms and signs have also been developed 
such as the Fontaine and Rutherford classifications; these account for the severity of 
claudication and clinical indicators of critical ischaemia, e.g. resting pain, non-
healing ulcers, loss of sensory function and gangrene (Rutherford et al. 1997). A 
more recent classification system suitable for patients with any signs of critical 
ischaemia (WIfI = wound, ischaemia and foot infection) combines assessment of 
wound depth, ABI or toe pressure measurements and presence and severity of 
infection (Mills et al. 2014) with a higher score indicating greater threat of limb loss 
and urgent need for revascularisation (Aboyans et al. 2018).  
Patients with PAD have suffered from under-recognition, both by diagnosis of the 
condition per se and management of the usual risk factors (Khan et al. 2007) despite 
it being the third most common manifestation of atherosclerotic disease after 
coronary artery disease and stroke, and becoming increasingly common worldwide 
(Fowkes et al. 2013). In a large study, the prevalence of peripheral arterial disease 
was 29%, and 16% had cardiovascular or cerebrovascular manifestations as well in 
a population of almost 7000 subjects aged 50 through 69 years with a history of 
smoking or diabetes (Hirsch et al. 2001). Notably, the management of the 
conventional risk factors was poorer in patients with peripheral disease only, 
compared to those with clinical coronary or cerebrovascular manifestations. The 
epidemiological results are in line with previous data where the prevalence has been 
20-30 % in adult or elderly populations (Meijer et al. 1998; Diehm et al. 2004). ABI 
tends to worsen along with advancing age and this is associated with common 
manageable risk factors of cardiovascular disease (Kennedy et al. 2005).  
PAD has a major impact on cardiovascular morbidity and mortality, independent of 
other clinical manifestations or risk factors of cardiovascular disease. It has been 
proposed that a decreased ABI reflects the overall atherothrombotic burden in the 
vascular tree (Fowkes et al. 2006). There is strong evidence of increased mortality 
due to cardiovascular causes in patients with severe symptomatic PAD (Criqui et al. 
1992; Newman et al. 1999) and low ABI is associated with increased risk of 
cardiovascular disease independent of other risk factors (Wild et al. 2006). On the 
other hand, even modest or moderate decreases in ABI (<0.9 or <0.8) have been 
associated with increased prevalence of cardiovascular disease and incidence of 
cardiovascular events (Newman et al. 1993; Violi et al. 1996; Heald et al. 2006). 
Importantly, symptomatic intermittent claudication has a low sensitivity for PAD 
and was present in a small fraction of patients in most of the studies (Newman et al. 
1999; Meijer et al. 1998; Criqui et al. 1996) and the risk of death and cardiac events 
seems to be the same in asymptomatic disease as in patients with claudication (Leng 
et al. 1996; Fisher et al. 2008). Furthermore, the increased mortality associated with 
PAD can be effectively reduced with adequate secondary prevention therapies 
(Pande et al. 2011). Therefore, a better early recognition of PAD and treatment of 
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predisposing factors is needed to reduce overall morbidity and mortality in these 
patients. However, the accuracy of ABI to detect PAD in its early stage may be 
insufficient (Crawford et al. 2016) and current evidence does not support screening 
of asymptomatic patients (Alahdab et al. 2015; Guirguis-Blake 2018). 
2.2.2.2 Clinical management of PAD 
Management of PAD involves identification and treatment of risk factors 
(hypertension, diabetes), lifestyle intervention (smoking cessation, exercise) and 
pharmacologic therapy such as antithrombotic drugs and statins (Hankey et al. 2006). 
Exercise training is essential in the conservative treatment of PAD (Gardner and 
Poehlman 1995; Watson et al. 2008) and endovascular therapies such as 
percutaneous transluminal angioplasty (PTA) should always be accompanied with 
exercise counsel (Mazari et al. 2010). Urgent restoration of circulation by PTA or 
surgical means is needed in severe cases such as acute or critical ischaemia or when 
response to conservative treatment is insufficient (Tendera et al. 2011; Gerhard-
Herman et al. 2017; Aboyans et al. 2018). However, there seems to be no long-term 
benefit of endovascular therapy over exercise training in intermittent claudication 
(Spronk et al. 2009; Pandey et al. 2017). Acetylsalicylic acid alone seems to be less 
effective than PTA in preventing short and long-term disease progression but the 
long-term effect on quality of life is controversial (Whyman et al. 1996; Whyman et 
al. 1997), illustrating the need for more aggressive pharmacologic secondary 
prevention. However, current evidence supports the use of acetylsalicylic acid and 
statins as the mainstay of treatment with antiplatelet combination therapy or oral 
anticoagulation recommended only for certain high-risk patient groups (Dagher and 
Modrall 2007; Belch et al. 2010; Tendera et al. 2011). Exercise training and 
endovascular or surgical procedures are all superior to pharmacological therapy in 
patients with intermittent claudication (Malgor et al. 2015). In patients unsuitable for 
PTA, surgical procedures, e.g. endarterectomy, femoro-femoral cross-over and 
femoro-popliteal bypass, can be considered.  
The choice between treatment options is made on a case-by-case basis since the 
evidence from randomised controlled studies comparing different treatment options 
(including optimised pharmacological therapy) is limited (Antoniou et al. 2017). 
While a primary PTA may improve walking distance and quality of life more rapidly, 
there seems to be no clear long-term benefit over successful conservative treatment 
(Murphy et al. 2012; Malgor et al. 2015). Patients not responding favourably to 
lifestyle counsel, exercise therapy and medication should be evaluated for 
endovascular or surgical interventions unless there are excessive risks for 
postoperative complications (Aboyans et al. 2018). Endovascular therapy is optimal 
in hemodynamically significant proximal stenoses (Indes et al. 2013; Aboyans et al. 
2018) in which maintenance of long-term patency is better than in distal lesions that 
are also more frequently associated with diffuse disease and limited benefit of 
invasive therapies (Kashyap et al. 2008; Tendera et al. 2011; Gerhard-Herman et al. 
2017). PTA can also be preferred in patients with high surgical risk (Antoniou et al. 
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2017) and patency after angioplasty can be improved by stent implantation (Kashyap 
et al. 2008). Surgery may increase long-term amputation-free survival as opposed to 
angioplasty and is often the best option for extensive femoro-popliteal stenoses but 
is associated with a higher risk of cardiovascular complications (Adam et al. 2005; 
Bradbury et al. 2010, Tendera et al. 2011; Aboyans et al. 2018). Finally, amputation 
remains as the last option for patients with critical ischaemia unsuitable for any 
means for revascularisation. Regardless of which treatment option is chosen, 
smoking cessation, exercise training and pharmacological management of risk 
factors such as dyslipidemia, hypertension and diabetes are essential (Aboyans et al. 
2018).  
2.3 Epidemiology, pathophysiology and clinical features of OSA 
2.3.1 Epidemiology of OSA 
OSA is a common health hazard in western societies. It is estimated that 
approximately 2% of females and 4% of males in general population are afflicted by 
the condition (Young et al. 1993; Bixler et al. 1998). However, these percentages 
should be used to refer to the prevalence of OSA syndrome, i.e. symptomatic OSA 
(e.g. heavy snoring or excessive sleepiness). OSA, in general, is apparently much 
more common. According to extensive data from Spain, the prevalence of at least 
mild OSA is 26% in women and 28% in men, aged 30-70 years (Durán et al. 2001). 
The prevalence of moderate or severe OSA has been estimated to be 1 in 15 (Young 
et al. 1993). Therefore, OSA becomes rapidly more common with advanced age. 
OSA is more prevalent in males but it becomes increasingly common in females 
after menopause (Bixler et al. 2001; Young et al. 2003). Increased sensitivity of 
modern recording techniques and scoring criteria may result in even higher 
prevalences of OSA, as shown by the HypnoLaus study, where the prevalence of 
moderate or severe sleep-disordered breathing (mostly obstructive) was 23.4 % in 
women and 49.7 % in men (Heinzer et al. 2015). These results suggest that the 
current AHI criteria defining a clinically relevant OSA disease may need to be 
revised. 
2.3.2 Clinical presentation of OSA 
OSA is characterised by repeated episodes of nocturnal hypoxemia, caused by 
occlusion or significant narrowing of the upper airway as the respiratory lumen 
collapses due to negative intraluminal pressure. An arousal or awakening is usually 
required to restore airway patency, resulting in fragmented sleep (Hudgel 1992; 
Deegan and McNicholas 1995; Patil et al. 2007; Mannarino et al. 2012). Turbulent 
airflow in a collapsing lumen causes vibration trauma and inflammation in the 
pharyngeal soft tissue (Hudgel 1992) and promotes snoring, a common symptom of 
OSA. The prevalence of at least mild OSA has been shown to be approximately one 
third and one fifth of habitually snoring men and women, respectively (Young et al. 
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1993). In the Sleep Heart Health Study, 86% of patients with at least moderate OSA 
were snorers, and those reporting heavy snoring and frequent breathing cessations 
had an up to four-fold greater likelihood of having at least moderate OSA (Young et 
al. 2002). Sleep fragmentation due to repeated episodes of hypoxemia, arousals and 
awakenings causes non-restorative sleep and excessive daytime sleepiness (EDS) 
(Punjabi et al. 1999; Punjabi et al. 2002). Sleepiness contributes to disability, 
decreased quality of life and increased risk for motor vehicle accidents.  
2.3.3 Pathophysiology of OSA 
2.3.3.1 Anatomical factors 
Obstructive apnoea results from interactions between a structurally narrow upper 
airway and decreasing muscle tone during sleep, which is not sufficiently 
compensated by the phasic contractions of upper airway dilator muscles during 
inspiratory efforts (Hudgel 1992; Deegan & McNicholas 1995; Patil et al. 2007; 
Mannarino et al. 2012). The upper airway between the hard palate and the larynx is 
a collapsible soft tissue tube surrounded by over twenty muscles that maintain its 
patency during normal breathing. Upper airway patency is dependent on the function 
of these muscles; the tensor palatini and the tongue that is mostly formed by the 
genioglossus muscle are the most important determinants of pharyngeal space 
(Pierce et al. 2007). Therefore, increased collapsibility may result from alterations 
in the anatomical structures or in the function of the muscles (Polo et al. 1991; Patil 
et al. 2007). 
Narrowing of the upper respiratory lumen may result from several cephalometric 
characteristics. These include congenital or traumatic anomalies of the nose and 
palate, shortening of the mandible manifesting as micro- or retrognatia and retro-
positioning of the maxilla (Watanabe et al. 2002). Obesity affects airway size by 
several mechanisms, acting together with the other anatomic features that predispose 
to OSA (Watanabe et al. 2002). Accumulation of adipose tissue adjacent to the 
airway is greater in patients with OSA than in body mass index (BMI) -matched 
controls (Li et al. 2012). While the amount of parapharyngeal fat is related to the 
severity of OSA (Shelton et al. 1993), the narrowing of the airway is associated with 
thickening of the lateral pharyngeal walls rather than enlargement of the 
parapharyngeal fat pads (Schwab et al. 1995).  
Taken together, OSA is associated with fat accumulation in the neck that compresses 
the pharynx mechanically, offsetting the dilatory function of neck muscles and 
increased neck circumference is the most reliable anatomical feature that predicts 
OSA in obese individuals (Davies & Stradling 1990; Katz et al. 1990). In morbid 
obesity, respiratory stress is increased by the sheer weight of the abdominal fat. 
Supine position promotes occlusion of the upper airway and is therefore detrimental 
to these patients (McEvoy et al. 1986), possibly by causing epiglottic obstruction 
(Marques et al. 2017). Finally, lung size in morbidly obese subjects is decreased, 
resulting in reduced upper airway size as well (Stadler et al. 2010). OSA has a 
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prevalence of 65-85 % in morbidly obese populations and is likely to be of at least 
moderate severity (Gasa et al. 2011; Leong et al. 2013; Kositanurit et al. 2018). In 
the European Sleep Apnoea Database (ESADA) of over 5000 patients with at least 
mild OSA, approximately 20-30 % were morbidly obese (BMI ≥35 kg/m2) with 30-
50 % presenting with metabolic or cardiovascular abnormalities (Hedner et al. 2011).  
2.3.3.2 Functional factors 
Activation of the respiratory pump muscles creates a negative pressure that pulls the 
pharyngeal walls toward each other (Bernoulli phenomenon), compromising airway 
patency (Badr 1998). Upper airway dilator muscles, including the genioglossus 
muscle, contract and stabilise the lumen to prevent its collapse (Henke et al. 1991; 
McGinley et al. 2008). This is facilitated by arterial chemoreceptors responding to 
increased CO2 (Onal et al. 1981; Lo et al. 2006). Increased respiratory resistance also 
stimulates the dilator muscles and the diaphragm in a parallel fashion (Patrick et al. 
1982). There is physiological decrease in the tone of these muscles during sleep due 
to general muscle relaxation that increases upper airway resistance (Mezzanotte et 
al. 1996; Lo et al. 2007) and the genioglossus muscle requires adequate CO2 levels 
to respond to inspiratory loading (Stanchina et al. 2002). In patients with OSA, the 
compensatory activity of this muscle is compromised during sleep (Mezzanotte et al. 
1996; McGinley et al. 2008). 
In addition to the respiratory drive to the dilator muscles, conductance of the upper 
airway is determined by lumen size, resistance to airflow and several other factors 
that influence collapsibility. First, reduced cross-sectional diameter renders the 
lumen more collapsible, and obesity is associated with decreased pharyngeal size 
(Morrell et al. 1998). Second, anatomical factors that increase airway resistance, 
promote collapsibility as ventilatory drive and negative intraluminal pressure are 
enhanced. For example, a naturally long pharynx is more prone to occlusion 
(Yamashiro & Kryger 2012). Third, abnormal shape of the lumen that is seen in 
apnoeic patients may compromise the ability of the surrounding muscles to maintain 
patency (Schwab et al. 1993). Finally, obesity is associated with decreased 
pharyngeal closing pressure and increased airway collapsibility (Genta et al. 2014). 
Taken together, all factors that influence collapsibility of the upper respiratory tract, 
define the closing pressure of the lumen. This pressure threshold also depends on 
sleep stage and is highest (i.e. less negative closing pressure and more collapsible 
airway) during rapid eye movement (REM) sleep (Carberry et al. 2016). The 
pressure threshold is approximately 6-8 cmH2O in healthy subjects; in apnoeic 
patients or snorers without apnoea it is less negative (around 1.5 cmH2O), or even 
positive in severe OSA (Gleadhill et al. 1991; Genta et al. 2014).  
Synchronisation of respiratory drive to the upper airway dilators and the respiratory 
pump muscles plays an important role in the preservation of upper airway patency 
(Hudgel 1992). Normally, when respiratory drive increases, activation of the 
pharyngeal dilator muscles precedes that of the diaphragm and thoracic wall muscles 
(Strohl et al. 1980). Consequently, the upper airway is stabilised before 
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augmentation of negative intraluminal pressure. While the same appears to be true 
in patients with OSA during non-apnoeic breaths, desynchronization of this neural 
drive has been observed during obstructed breathing efforts (Hudgel & Harasick 
1990). The activity of the dilator muscles has also been found to oscillate between 
conditions that predispose to apnoea and those that favour airway patency depending 
on the force of the inspiratory drive (Hudgel et al. 1987). These mechanisms are in 
conjunction with the concept that neural drive to respiratory muscles is increased in 
patients with OSA but imbalance between the activity of respiratory pump muscles 
and upper airway dilators results in obstruction. In addition, a low arousal threshold 
seems to predispose to worsening of OSA; arousals are not necessarily needed to 
maintain or restore airway patency but may promote ventilatory instability instead 
(Younes 2004).   
OSA must be discriminated from central sleep apnoea (CSA) where cessation of 
breathing is caused by lack of central drive regulated by the respiratory centre. A 
pure CSA is very rare unless associated with congestive heart failure. However, the 
difference between OSA and CSA is not always clear-cut. Instead, there is 
considerable overlapping of the two conditions in which both peripheral and central 
chemoreceptors are likely to play a role. The respiratory response to CO2 can be 
measured with controller gain (i.e. the ratio of change in ventilation to change in 
CO2). Other measures are plant gain (i.e. CO2 response to change in ventilation) and 
feedback gain (i.e. speed of feedback signal, determined mainly by cardiac output). 
Loop gain can be calculated from these three measures (i.e. controller gain × plant 
gain × feedback gain). High controller gain is characteristic to CSA and is related to 
heart failure and autonomic dysfunction (Solin et al. 2000). Following a collapse of 
the airway and subsequent arousal, hyperventilation eventually causes hypocapnia, 
decreasing respiratory drive, promoting either central apnoea or weakening of upper 
airway muscle tone. Insufficient central drive may therefore maintain obstruction 
after respiratory efforts recommence. Fitting into this paradigm, decreased CO2 
reserve which is typical in CSA associated with heart failure (Xie et al. 2002) is also 
characteristic to predominant OSA (i.e. OSA with concomitant central apnoea 
episodes) as opposed to pure OSA with exclusively obstructive episodes (Xie et al. 
2011). In another study, decreased CO2 reserve was associated with increased 
controller gain in patients with OSA predisposing to central apnoea (Salloum et al. 
2010). Ventilatory control instability (measured with increased loop gain) is also 
related to the severity of OSA (Younes et al. 2001; Wellman et al. 2004).  
2.3.4 OSA as a multifactorial phenomenon 
In  summary of  the  above,  upper  airway  muscle tone decreases during sleep and 
occlusion of the lumen results when this is combined with other factors that 
compromise airway patency. Arousal restores airway patency but causes sleep 
fragmentation. Disturbances in oxygen and CO2 tensions play a crucial role by 
disrupting central respiratory drive to the dilator muscles. Furthermore, ventilatory 
response to CO2 appears to be disturbed in obese patients with OSA in a pattern that 
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destabilises the function of these muscles (Hudgel et al. 1998). While high loop gain 
is a primary factor in CSA, it is also included in a number of traits that predispose to 
OSA, such as pharyngeal anatomy, upper airway muscle responsiveness during sleep 
and arousal threshold (White 2005). Thus, the pathophysiology of upper airway 
obstruction in OSA is multi-factorial and involves disturbance in the overall 
respiratory homeostasis – and in a significant proportion of patients – together with 
mechanical obstruction. A latter review emphasises that the aetiology of OSA varies 
between different patient groups; the involved factors include chemical respiratory 
drive to the pharyngeal muscles, effect of age on airway collapsibility, loop gain, 
arousal threshold and overall ventilatory control stability (White & Younes 2012). 
Furthermore, different phenotypes of OSA were observed regarding the age of the 
patient; either airway collapsibility or sensitive ventilatory control was the dominant 
pathophysiological feature in older and younger adults, respectively (Edwards et al. 
2014). 
2.3.5 Diagnosis and treatment of OSA 
OSA is conventionally diagnosed with polysomnography (PSG) which has long been 
considered as the gold standard. The PSG includes the electroencephalogram (EEG), 
electro-oculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse 
oximeter for monitoring of arterial oxyhemoglobin saturation and respiratory flow 
measurement with nasal cannula. This setting allows evaluation of overall sleep 
quality, minute-by-minute definition of sleep stages, apnoea status and identifies 
other sleep-related phenomena such as leg movements or teeth grinding (bruxism). 
Detection of respiratory movement efforts with thoracic and abdominal induction or 
piezo-electric belts is recommended to differentiate OSA from CSA. Also, the nasal 
cannula can be used to measure end-tidal CO2 (etCO2) from expiratory airflow 
(American Academy of Sleep Medicine Task Force 1999).  
Apnoea and hypopnoea are identified from the respiratory flow signal and the 
apnoea-hypopnoea index (AHI) is expressed as the number of events per hour of 
sleep. An AHI >5/hour is the most used cut-off level in current literature. The 
American Academy of Sleep Medicine classifies sleep apnoea as mild (AHI 5-
15/hour), moderate (AHI 15-30/hour) and severe (AHI >30/hour) with the according 
thresholds in the AHI (American Academy of Sleep Medicine Task Force 1999). 
The nature of sleep apnoea is defined as obstructive or central according to which 
kind of apnoea episode is predominant. The gold standard to distinguish obstructive 
and central apnoea episodes is to measure the changes of intrathoracic pressure via 
an oesophageal pressure transducer (Baydur et al. 1982). To avoid the invasiveness 
of this technique, this is usually done by utilizing piezo-electric or induction belts 
that measure movements of the abdominal and thoracic wall to detect respiratory 
efforts and progressive desynchronisation between the movements of the abdominal 
wall and the rib cage (Lévy et al. 1992). Another non-invasive method is to measure 
the pulse transit time (PTT) from the R-peak of the electrocardiogram and the 
peripheral pulse wave detected with a pulse oximeter. This technique has been 
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validated against the gold standard for differentiation of both obstructive apnoea and 
hypopnoea episodes from central ones (Argod et al. 1998; Argod et al. 2000).    
Currently, the most widely applied treatment for moderate-to-severe OSA is CPAP 
and its variations such as bi-level positive airway pressure and adaptive servo 
ventilation (ASV) therapies. A CPAP device maintains a positive airway pressure by 
delivering constant airflow via nasal or facial mask to the upper airway. The airway 
pressure serves as a pneumatic splint that maintains upper airway patency throughout 
the respiratory cycle during sleep (Sullivan et al. 1981). Numerous studies have 
shown that CPAP ameliorates sleep deprivation, decreases the subjective symptoms 
(snoring, EDS) and improves quality of life (Yamamoto et al. 2000; Siccoli et al. 
2008; Avlonitou et al. 2012). 
2.4 Sleep apnoea and cardiovascular disease 
2.4.1 Epidemiology of OSA in cardiovascular disorders 
2.4.1.1 OSA and clinical cardiovascular disease 
OSA is associated with a plethora of cardiovascular co-morbidities and among 
patients suffering from various manifestations of atherosclerotic disease its 
prevalence is much higher than in general population. Approximately 30-40 % of 
patients with coronary artery disease (Peker et al. 1999; Mooe et al. 2001) and 60-
70% of patients with stroke or transient ischaemic attack (Wessendorf et al. 2000; 
Rola et al. 2007; Joo et al. 2011) appear to have OSA. There is also evidence that 
OSA precedes incident stroke, increases mortality (Yaggi et al. 2005; Campos-
Rodríguez et al. 2014) and that OSA hampers recovery from ischemic stroke (Yan-
fang & Yu-ping 2009). Another study showed a high prevalence (ca. 64 %) of 
moderate or severe OSA (AHI >15/hour) in patients undergoing percutaneous 
coronary intervention or coronary artery bypass grafting (Glantz et al. 2013). In the 
Sleep Heart Health Study, OSA carried a 58 % and 68 % increased risk of incident 
heart failure and coronary artery disease, respectively (Gottlieb et al. 2010). This 
effect was seen only in men with severe OSA, compared to those with no OSA. In 
the Wisconsin Sleep Cohort Study, the incidence of coronary artery disease was 2.6 
times higher in patients with  severe  untreated  OSA  than  in  those  without (Hla 
et al. 2015). Moreover, patients with OSA have been described to be prone to 
myocardial ischaemia even in the absence of clinical coronary artery disease (Hanly 
et al. 1993). Increased overall and all-cause mortality related to OSA in 
cardiovascular and cerebrovascular disease has been observed in two meta-analyses 
(Ge et al. 2013; Xie et al. 2014). 
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2.4.1.2 OSA and cardiovascular risk factors 
OSA has been shown to be independently associated with several key risk factors of 
atherosclerosis. Hypertension in patients with OSA is not caused by obesity alone as 
shown in large-scale population-based studies (Grote et al. 1999; Peppard et al. 2000; 
Nieto et al. 2000). It has also been postulated that multi-drug dependent or drug-
resistant hypertension is independently associated with OSA (Lavie et al. 2001; 
Logan et al. 2001). The pathophysiological interaction between hypertension and 
OSA involves hypoxia-mediated sympathetic activation, oxidative stress, systemic 
inflammation and endothelial dysfunction (Fletcher 2003; Jelic et al. 2008). 
Activation of the renin-angiotensin-aldosterone system is also likely to play a role in 
the development of hypertension, and may also lead to worsening of OSA via airway 
narrowing due to fluid retention (Pratt-Ubunama et al. 2007; Dudenpostel et al. 
2012). Finally, improvement in both nocturnal and 24-hour blood pressure has been 
achieved by CPAP treatment in patients with OSA and resistant hypertension 
(Martínez-García et al. 2013). 
It has been a matter of controversy whether insulin resistance and type 2 diabetes 
mellitus are independently associated with OSA or share obesity as a common risk 
factor (Sharma et al. 2007). However, other studies have been able to demonstrate 
impaired glucose tolerance in patients with OSA independent of obesity (Ip et al. 
2002; Punjabi et al. 2002). Afterwards, increased insulin resistance was shown in 
obese OSA patients independent of obesity but associated with EDS instead (Barcelo 
et al. 2008). In the Sleep Heart Health Study, higher prevalence of impaired glucose 
tolerance in OSA patients was also confirmed in both obese and non-obese 
population (Seicean et al. 2008). In a more recent study, metabolic syndrome 
including insulin resistance was highly prevalent (51 %) in patients with OSA and 
increased with the severity of OSA, irrespective of EDS (Bonsignore et al. 2012).  
2.4.1.3 Asymptomatic OSA 
It is not fully established whether the presence of EDS is relevant in determining the 
cardiovascular risk caused by OSA (Kendzerska et al. 2014). In patients with heart 
failure or stroke, EDS is less frequent and does not adequately predict OSA (Arzt et 
al. 2006; Arzt et al. 2010). While EDS is associated with OSA severity, diabetes and 
carotid atherosclerosis (Saletu et al. 2008), early signs of atherosclerosis have also 
been demonstrated in minimally symptomatic and asymptomatic OSA (Kohler et al. 
2008; Drager et al. 2010). However, one cohort study showed increased overall 
mortality in older adults with OSA only in the presence of EDS (Gooneratne et al. 
2011). The controversies may result from different patient populations; subjects 
referred to a sleep laboratory due to suspected OSA are more likely to have EDS as 
well. 
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2.4.2 Consequences of OSA in cardiovascular disease 
2.4.2.1 OSA-related coronary vascular events 
Concomitant OSA is very common in patients presenting with acute coronary events 
with a prevalence of up to 50-60 % in AMI and acute coronary syndrome (Lee et al. 
2009; Lee et al. 2011; Schiza et al. 2012). However, some studies have shown a 
reduction in the prevalence of OSA during follow-up after clinical recovery from the 
acute phase of a coronary event (Skinner et al. 2005; Schiza et al. 2012; Buchner et 
al. 2012). These findings may explain earlier results showing no increase in mortality 
associated with OSA diagnosed concurrently with acute coronary syndrome (Mehra 
et al. 2006). An early study showed that even mild OSA is independently associated 
with AMI in surviving (PSG performed post-AMI) male patients (Hung et al. 1990). 
Furthermore, OSA predicts poor prognosis and impaired recovery of left ventricular 
function following AMI as well as increased overall mortality in coronary artery 
disease (Peker et al. 2000; Nakashima et al. 2006; Xie et al. 2016). In addition, poorer 
clinical outcome following percutaneous coronary intervention, including less 
reduction in infarct size and increased risk of new coronary events has been 
demonstrated (Yumino et al. 2007; Buchner et al. 2014; Lee et al. 2016). Poor 
recovery following coronary events may relate to severe endothelial dysfunction that 
has been shown in patients with moderate-to-severe OSA (Sert Kuniyoshi et al. 
2011). 
2.4.2.2 Mechanisms of OSA-related cardiovascular disease 
OSA is associated with sympathetic activation and other pathophysiological 
mechanisms that are also the key factors in the development of cardiovascular 
disease, including pressor surges, oxidative stress, systemic inflammation and 
endothelial dysfunction (Somers et al. 1995; Kato et al. 2000; Jelic et al. 2008). 
Intermittent hypoxia is a potential cause for sympathetic activation as OSA has been 
shown to induce adrenergic overdrive in metabolic syndrome via hypoxia-mediated 
chemoreceptor activation with impaired baroreflex control (Grassi et al. 2010). 
Tonic chemoreflex activation and augmented autonomic chemoreflex responses 
have been demonstrated in OSA and metabolic syndrome (Narkiewicz et al. 1998; 
Narkiewicz et al. 1999; Trombetta et al. 2013). The effect of repeated nocturnal 
hypoxia is aggravated by deficient parasympathetic inhibition due to lack of normal 
lung inflation and persists during wakefulness (Morgan 1996; Leuenberger et al. 
2005; Mansukhani et al. 2014). The risk of AMI, arrhythmias and stroke are likely 
to be increased if pressor surges are insufficiently countered by the baroreflex. 
Interestingly, the incidence of AMI in patients with OSA peaks from 6 a.m. to 12 
a.m. as opposed to the early morning hours in the general population (Kuniyoshi et 
al. 2008). 
In addition to the ANS dysfunction, several other mechanisms have been identified. 
These include reduced stroke volume as well as intra-thoracic pressure swings 
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caused by forced respiratory efforts that increase left ventricular afterload, impair 
diastolic filling and predispose to left ventricular hypertrophy (Bradley et al. 2001). 
Moreover, hypoxemia enhances platelet aggregation (Bokinsky et al. 1995), 
promotes oxygenation of lipoproteins (Luyster et al. 2012) and systemic 
inflammation via production of oxygen radicals (Yokoe et al. 2003; Ryan et al. 
2005), contributing to endothelial dysfunction. Accordingly, oxidative stress has 
been postulated as the key factor and the unifying paradigm underlying the 
cardiovascular co-morbidities and metabolic disorders associated with OSA (Lavie 
2009; Lavie & Lavie 2009). Furthermore, OSA combined with metabolic 
disturbances has been suggested to be a pivotal factor in the overall pathogenesis of 
atherosclerosis (Lorenzi-Filho & Drager 2007).   
2.4.3 Sleep-disordered breathing and heart failure 
Congestive heart failure is also associated with OSA (Ferrier et al. 2005). In addition 
to the detrimental effect of intermittent hypoxia on left ventricular systolic function, 
OSA increases the risk of atrial fibrillation, further contributing to decreased cardiac 
output (Gami et al. 2004; Gami et al. 2007). However, central apnoea is more 
characteristic to heart failure (Vazir et al. 2007) and CSA seems to correlate with its 
clinical severity (Oldenburg et al. 2007; Javaheri et al. 2016). The presence of 
Cheyne-Stokes respiration predicts mortality in severe heart failure with LVEF <30 
% (Brack et al. 2007) and AHI ≥30/hour is an independent prognostic factor in 
patients with LVEF ≤35 % (Lanfranchi et al. 1999). Imbalance in arterial gas 
tensions and decreased body stores of oxygen and CO2 are essential in the 
pathophysiology of Cheyne-Stokes respiration. CSA is very rare in general 
population and has a prevalence of less than 1 % in the absence of heart failure 
(Bixler et al. 1998; Bixler et al. 2001). Overlapping of OSA and CSA may occur in 
patients with heart failure with varying predominance (Javaheri et al. 1998; Javaheri 
et al. 2017). When the predominant type of apnoea is obstructive, moderate OSA 
(AHI ≥15/hour) increases mortality but the benefit of treatment is not clear (Wang 
et al. 2007).   
2.4.4 Effect of treatment of OSA and CSA in cardiovascular disease 
2.4.4.1 Effect of CPAP and ASV therapies 
The deleterious effects of OSA in symptomatic patients can potentially be attenuated 
with CPAP therapy. In patients with severe OSA (AHI ≥30/hour), an observational 
study showed that CPAP reduces the risk for fatal and non-fatal cardiovascular 
events (Marin et al. 2005). Women with severe OSA also have an increased risk of 
cardiovascular death  that  was  alleviated with  CPAP  treatment  in  another 
observational study (Campos-Rodríguez et al. 2012). Other thresholds for apnoea 
severity have also been applied, e.g. AHI ≥15/hour and AHI ≥20/hour (Cassar et al. 
2007; Martínez-García et al. 2009). Another study showed a correlation between the 
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AHI and cardiac structural and functional deterioration that was reversible with 
CPAP in patients with hypertension and severe OSA but without clinical cardiac 
disease (Shivalkar et al. 2006). Elderly patients with severe OSA also achieve 
reduced risk of cardiovascular death when adhering to CPAP, i.e. when it is used for 
more than four hours every night (Martínez-García et al. 2012).  
The data showing the benefit of CPAP have been obtained from observational or 
retrospective studies but there is a shortage of confirming results from randomised 
controlled trials (McEvoy et al. 2016; Peker et al. 2016). This problem has also been 
acknowledged in recent meta-analyses but the lack of efficacy may relate to 
insufficient adherence to CPAP (Abuzaid et al. 2017; Wang et al. 2018). 
Nevertheless, CPAP lowers blood pressure in severe OSA and resistant hypertension 
which is likely to reduce cardiac risk (Martínez-García et al. 2013; Bratton et al. 
2014). The benefit may depend on the adherence to treatment. Indeed, there seems 
to be a favourable effect on cardiac outcome with a CPAP usage of more than four 
hours per night (Peker et al. 2016; Abuzaid et al. 2017). Results from patients with 
heart failure and predominant central apnoea are even more controversial. CPAP 
decreases short-term mortality in heart failure patients with CSA (Sin et al. 2000) 
but there is no evidence of improvement on long-term survival despite attenuation 
of the AHI, left ventricular dysfunction and sympathetic activation (Bradley et al. 
2005). Another study suggested a potential benefit of early CPAP for CSA (Arzt et 
al. 2007) but ASV (i.e. adjusted CPAP based on the detection of apnoeas) seems to 
increase mortality in patients with heart failure and CSA (Cowie et al. 2015; 
Eulenburg et al. 2016; Woehrle et al. 2017). The mechanism of the increased 
mortality associated with ASV therapy in heart failure remains an open question. 
2.4.4.2 Treatment effects of CPAP in asymptomatic patients 
In controlled studies with nasal and sham CPAP, daytime vigilance or blood pressure 
could not be improved with CPAP in asymptomatic (without sleepiness) subjects 
(Barbé et al. 2001; Robinson et al. 2006). In a later trial, the overall cardiovascular 
risk was not reduced by CPAP in minimally symptomatic OSA patients (Craig et al. 
2012). Another randomised controlled study showed no reduction in the incidence 
of hypertension or cardiovascular events in non-sleepy OSA patients treated with 
CPAP (Barbé et al. 2012). A more recent meta-analysis showed that lipid profiles in 
patients with OSA can be improved with CPAP therapy and this effect is most 
prominent in moderate to severe OSA with daytime sleepiness (Lin et al. 2015). 
However, there seems to be no effect on inflammatory markers (Stradling et al. 
2015). Thus, systematic screening for OSA is not currently encouraged due to the 
limited clinical applicability of current screening tools and the modest effect on most 
outcomes (Jonas et al. 2017).  
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2.4.5 OSA and postoperative complications 
OSA is recognized to carry a remarkable risk of various postoperative complications. 
However, the available data are mostly limited to respiratory complications or 
surrogate endpoints. These include prolongation of intensive care, or respiratory 
complications such as pulmonary atelectasis and transient desaturations requiring 
reintubation or supplemental oxygen (Gupta et al. 2001, Hwang et al. 2008; Mador 
et al. 2013). Perioperative CPAP therapy and postoperative supplemental oxygen 
have been tried to improve oxygenation and reduce the AHI postoperatively (Liao et 
al. 2013; Liao et al. 2017). Some studies have also demonstrated a decrease in 
postoperative cardiovascular and cardiopulmonary complications by CPAP (Mutter 
et al. 2014; Abdelsattar et al. 2015), while other trials have failed to do so (Mador et 
al. 2013; Nagappa et al. 2015). Combination of different screening and monitoring 
tools may be useful in identifying patients suitable for postoperative management of 
OSA (Gali et al. 2009). The American Society of Anesthesiology Task Force has 
advocated the use of CPAP in the preoperative management of surgical patients with 
severe OSA (Gross et al. 2006). However, there is insufficient evidence whether this 
would improve postoperative outcome in these patients. Similar recommendations 
have been given in later Task Force reports; the evidence of a beneficial effect of 
CPAP therapy for the prevention of these events, preceding or following surgery, is 
controversial (Chung et al. 2016; Opperer et al. 2016).   
2.5 Postoperative cardiovascular complications in advanced 
atherosclerosis 
2.5.1 Postoperative complications in non-cardiac surgery 
Cardiac complications (i.e. AMI, cardiac arrest, cardiac death) following non-
cardiac surgery remain an issue of remarkable clinical impact. This is especially true 
in patients undergoing major vascular surgery where the incidence of postoperative 
myocardial infarction is high. Approximately 10-20 % and up to 30 % of patients 
undergoing sub-inguinal vascular surgery suffer a perioperative or postoperative 
AMI (Landesberg et al. 2003; Levy et al. 2011) and myocardial ischaemia occurs in 
an even higher proportion (Mangano et al. 1990). Perioperative AMI accounts for 
approximately one third of in-hospital cardiac deaths and predicts new 
cardiovascular events also in the six months following surgery (Devereaux et al. 
2005). The 30-day mortality of these patients is approximately 10-25 % (Badner et 
al. 1998, Devereaux et al. 2005, Devereaux et al. 2011). Furthermore, the overall 
five-year mortality of patients undergoing sub-inguinal vascular surgery is 
approximately 30 %, mostly due to cardiac complications (Conte et al. 2001; 
Landesberg et al. 2003; Levy et al. 2011).  
The high cardiac mortality following vascular surgery relates to the fact that these 
patients typically have a severe systemic atherosclerosis, as reflected by the presence 
of PAD itself. In an early study, pre-existing clinical coronary artery disease was a 
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major predictor of postoperative AMI in non-cardiac surgery (Ashton et al. 1993). 
However, subclinical coronary artery disease is common in patients undergoing 
vascular surgery and especially in those with PAD (Hirsch et al. 2001). Furthermore, 
postoperative myocardial ischaemia is frequently asymptomatic and silent AMI 
carries the same prognostic significance as symptomatic AMI (Deveraux et al. 2005; 
Devereaux et al. 2011). Therefore, more advanced risk stratification methods are 
needed to detect the patients at the highest risk of postoperative complications.  
2.5.2 Prediction and prevention of postoperative cardiac complications 
2.5.2.1 Current means for risk stratification and prevention 
To recognize patients at high risk of major cardiac complications, a variety of risk 
stratification methods have been employed. These involve risk scores based on 
presence and severity of underlying diseases such as diabetes, renal or heart failure 
and the overall severity of atherosclerosis. One of the most used scores is the Lee 
Revised Cardiac Risk Index (Lee et al. 1999). Based on these indices, patients can 
be referred to preoperative coronary revascularisation. Improvement on long-term 
survival has been demonstrated in intermediate-risk patients (Landesberg et al. 2007) 
and there is also evidence of possible benefit in high-risk patients (Boersma, 2001). 
Left ventricular ejection fraction (LVEF) can provide relevant information in 
patients determined to be at high risk according to clinical criteria, but its usefulness 
has been questioned especially in low-risk patients (Halm et al. 1996; Rohde et al. 
2001). Cardiac biomarkers such as natriuretic peptides can independently predict 
perioperative myocardial ischaemia and short-term postoperative cardiac events 
(Feringa et al. 2007; Karthikeyan et al. 2009). However, randomised trials have 
shown that preoperative coronary revascularisation does not improve outcome in 
intermediate-risk or high-risk patients, compared to conservative treatment 
(pharmacologic therapy) and can be omitted (Poldermans et al. 2006; Poldermans et 
al. 2007; Schouten et al. 2009). Accordingly, the controversies in the data regarding 
the benefit of interventions based on preoperative testing compromise the usefulness 
of currently used means of risk stratification as a basis for clinical decisions.  
2.5.2.2 Role of pharmacological therapy 
Some studies have shown that preoperative administration of beta-blocker therapy 
reduces the probability of postoperative cardiac events (Poldermans et al. 1999) and 
the protective effect of beta-blockers may even extend to two years after successful 
surgery (Poldermans et al. 2001). However, concerns have been raised over these 
studies and  the applicability of their results is being questioned. Statins may also 
be beneficial (O’Neil-Callahan et al. 2005; Feringa et al. 2007). The possible 
cardioprotective effect of beta-blockers, if any, may require tight control of heart rate 
which is likely to predispose to side effects (Feringa et al. 2006; Beattie et al. 2008). 
In addition, the benefit of these drug therapies has mostly been limited to prevention 
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of non-fatal events with no evidence of decreased overall mortality making any 
recommendation of routine preoperative beta-blocker therapy questionable 
(Devereaux et al. 2005; Bangalore et al. 2008). Indeed, a large randomised controlled 
trial showed that patients on metoprolol treatment had an increased overall mortality 
and incidence of stroke (in a 30-day follow-up) despite suffering less perioperative 
myocardial infarctions (Devereaux et al. 2008). Consequently, perioperative use of 
beta-blocker in patients of any age group undergoing non-cardiac surgery has been 
discouraged due to lacking evidence of any real benefit and high risk of side effects 
(Mostafaie et al. 2015; Blessberger et al. 2018). Perioperative administration of 
clonidine and acetyl salicylic acid have also been tried with no apparent
 benefit
 
(Devereaux et al. 2014; Devereaux et al. 2014). 
2.5.2.3 Open questions and future prospects 
The major difficulty hindering identification of patients at risk of peri- and 
postoperative cardiac events is the lack of profound understanding of the underlying 
pathophysiology. While the pathogenesis of non-operative AMI and coronary artery 
disease is well understood, such is not the case with peri- and postoperative AMI 
since findings in patients having suffered a fatal and non-fatal AMI are controversial 
(Devereaux et al. 2005). Whereas two thirds of fatal perioperative AMIs involve a 
left main or three-vessel disease, a plaque rupture or intra-arterial thrombosis is 
evident in only one third of the cases (Dawood et al. 1996; Cohen et al. 1999). 
Furthermore, non-fatal AMI occurs frequently without clinically relevant coronary 
stenosis (Ellis et al. 1996). These observations implicate that several other factors 
than the severity of coronary artery disease per se must have a crucial role in the 
pathogenesis of postoperative cardiac complications in patients undergoing non-
cardiac surgery. Therefore, more knowledge of the underlying pathophysiology and 
novel cost-effective risk stratification methods is needed. 
There is evidence that PAD is associated with small artery disease of the brain in the 
absence of clinical cerebrovascular disease (Longstreth et al. 2005). White matter 
lesions detected with magnetic resonance imaging (MRI) of the brain are common 
in patients with decreased ABI (Bots et al. 1993), implying that PAD is associated 
with cerebrovascular disease. Diffusion tensor imaging (DTI) is a novel MRI 
technique that assesses the microstructural integrity of brain white matter tracts, 
permitting quantitative measurements such as fractional anisotropy (FA). 
Decreasing FA reflects axonal loss (Jones et al. 1999) even in patients with no 
ischaemic changes in conventional MRI (O’Sullivan et al. 2001). These disruptions 
precede the development of lesions in conventional MRI (de Groot et al. 2013) and 
predict clinical stroke (Evans et al. 2016). Moreover, decreasing FA values are 
associated with increased morbidity and mortality in patients with PAD (Virtanen et 
al. 2014; van der Holst et al. 2016). In addition, the risk factors and early stages of 
atherosclerosis are associated with white matter microstructural damage (Segura et 
al. 2009; Gons et al. 2010; Falvey et al. 2013). Taken together, DTI has potential 
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value for risk stratification in patients with cardiovascular disease, the clinical utility 
of which remains to be defined. 
2.6 Heart rate variability 
2.6.1 Basic concepts of heart rate dynamics 
Decreased heart rate variability (HRV) and baroreflex function have been introduced 
as prominent risk factors of cardiovascular morbidity and mortality (Kleiger et al. 
1987; Farrell et al. 1991; Task Force of The European Society of Cardiology and 
The North American Society of Pacing and Electrophysiology 1996). In normal 
physiology, blood pressure surges caused by internal or external triggers are buffered 
by the baroreceptors. Consequently, parasympathetic vagal activation decreases 
heart rate and maintains blood pressure in a safe window (Kirchheim 1976). Thus, 
heart rate and blood pressure are normally regulated by complex interactions of the 
sympathetic and parasympathetic branches of the ANS; in cardiovascular disease, 
these  mechanisms are  disturbed (La Rovere et al. 2008).  As a result, pressor 
surges are inadequately countered by the baroreceptors, and heart rate is maintained 
at unsuitable levels. The resulting predomination of sympathetic tone is potentially 
deleterious to patients with compromised cardiovascular adaptability, predisposing 
to myocardial ischaemia, AMI, arrhythmias and cardiac death (La Rovere et al. 
1998). Baroreceptors of the carotid body are important in the baroreflex control of 
autonomic tone (Smit et al. 2002); HRV reflects efferent outflow (sympathetic vs. 
vagal) of the ANS to the heart (Malliani et al. 1991). Therefore, analysis of HRV can 
be used to assess autonomic dysfunction in various pathophysiological conditions 
although it must be acknowledged that alterations in HRV are not generated by 
sympathetic and vagal activation alone (Malik et al. 1993). 
2.6.2 Assessment of HRV 
2.6.2.1 Time and frequency domain methods 
Conventional assessment of HRV includes time and frequency domain analyses 
(Laitio et al. 2007). Statistical time domain measurements include standard deviation 
of the interval between normal R-peaks (SDNN) in the ECG (RR-interval, RRI of 
which normal-to-normal interval, NNI, is most often used), root mean square of the 
sum of successive differences (RMSSD) between adjacent RRI (i.e. beat-to-beat 
variability) and proportion of NNI >50 ms in duration (pNN50). In general, 
decreasing values in these parameters reflect depressed HRV due to compromised 
vagal heart rate control. While the total power of the HRV spectrum reflects overall 
autonomic activity, different contributions of the ANS as well as humoral and 
circadian rhythms are illustrated in the HRV spectrum as high frequency (HF; 0.15-
0.4 Hz), low frequency (LF; 0.04-0.15 Hz), very low frequency (VLF; 0.003-0.04 
Hz) and ultra-low frequency (ULF; ≤0.003 Hz) oscillations in heart rate. The power 
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of each frequency domain is expressed in the spectrum as the square of milliseconds 
(ms2). HF reflects rapid heart rate oscillations resulting from parasympathetic 
activation and a major part of HF power consists of physiologic sinus arrhythmia 
caused by normal respiration. LF, VLF and ULF consist of slow changes during 
longer periods due to sympathetic activation, metabolic and endocrinologic activity, 
circadian rhythms and temperature regulation. Of these, VLF and ULF are best 
determined from ECG recordings of several hours or days in duration (Task Force 
of The European Society of Cardiology and The North American Society of Pacing 
and Electrophysiology 1996). The LF/HF ratio is commonly used to express 
predominance of either aspect of ANS since LF and HF are (supposedly) mainly 
affected by sympathetic and vagal activity, respectively (Malliani et al. 1991). 
However, it does not reflect the absolute degree of ANS activity but rather the 
relative strength of sympathetic activity to parasympathetic tone (i.e. sympathetic 
activation increases the ratio) to a limited extent. In addition, both sympathetic and 
parasympathetic activation contribute to the LF component.  
Decreased HRV measured with the spectral parameters mentioned above predict 
increased mortality as late as one year following an AMI (Bigger et al. 1993). Later 
studies have shown that time domain measures of HRV lose their prognostic value 
in patients with AMI when early revascularisation is performed (Compostella et al. 
2016; Compostella et al 2017) whereas in an earlier study SDNN and LF measures 
retained some short-term predictive value (Coviello et al. 2013). The normalised 
units (nu) of LF and HF (ratio of the respective spectral power and total power, 
excluding VLF, multiplied by 100) are sometimes used instead of the absolute 
powers because they are less affected by the simultaneous change in total power 
(Task Force of The European Society of Cardiology and The North American 
Society of Pacing and Electrophysiology 1996). 
2.6.2.2 Non-linear methods 
Normal heart rate is known to uphold fractal dynamics, i.e. short-term changes 
reflect changes in the long term (Yamamoto & Hughson 1994; Yamamoto et al. 
1995). In disease states, such as severe heart failure, the fractal pattern disintegrates 
(Goldberger et al. 2002). This may result in completely random fluctuation of heart 
rate and poor cardiovascular adaptability to pressor surges and other detrimental 
events, increasing risk of AMI and sudden death. Complete obliteration of fractal 
correlation (loss of self-similarity) is known to occur in severe congestive heart 
failure (Poon & Merrill 1997). The adherence of HRV to fractal dynamics can be 
calculated by detrended fluctuation analysis (DFA) and is expressed by a fractal 
scaling exponent alpha (Peng et al. 1995). Alpha 1 reflects short-term fractal 
correlation properties of heart rate. A value of 1 represents high fractal correlation 
whereas low values (i.e. close to 0.5) reflect increasing randomness in heart rate and 
risk of ventricular arrhythmias. A scaling exponent value reflecting strong fractal 
correlation is a characteristic feature of complex physiological systems regulated by 
intricate feedback mechanisms (i.e. a healthy cardiovascular system). Conversely, 
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increasing randomness is associated with poorer outcome in coronary artery disease 
following AMI (Tapanainen et al. 2002) and bypass grafting (Laitio et al. 2000). 
Loss of fractal heart rate dynamics also independently predicts mortality in patients 
with post-AMI depressed LVEF (Mäkikallio et al. 1999; Huikuri et al. 2000) and 
even slightly decreased alpha 1 has been shown to be associated with cardiac death 
in a general elderly population (Mäkikallio et al. 2001). Fractal correlation of HRV 
during sleep has not been previously studied in patients with PAD undergoing 
vascular surgery.  
Other non-linear methods to quantify the regularity and predictability of an RRI time 
series are approximate entropy and sample entropy. Entropy reflects the likelihood 
that different epochs of any given length in a time series remain statistically similar 
to each other. Greater likelihood of similarity means low entropy (0.7 - 1.0) and 
lesser likelihood yields higher entropy values (close to 2.0). Sample entropy is the 
most reliable of these parameters. In short, it quantifies the irregularity of an RRI 
time series with increasing entropy reflecting higher complexity due to feedback 
regulation (Richman & Moorman 2000). 
2.6.3 HRV and postoperative morbidity and mortality 
Several earlier studies have shown that decreased HRV is linked with autonomic 
dysfunction and associated with cardiac death or myocardial infarction following 
major surgery or trauma (Filipovic et al. 2003; Mamode et al. 2001; Cooke et al. 
2006). Furthermore, studies involving patients with cardiovascular disease and 
cohort studies with elderly subjects have suggested HRV to be a more powerful 
predictor of mortality than established clinical parameters such as decreased LVEF 
(Tsuji et al. 1994; Bauer et al. 2006). Other studies have linked decreased HRV with 
haemodynamic instability during anaesthesia and surgery (Hanss et al. 2006). In 
patients undergoing coronary artery bypass grafting (CABG), studies have shown 
that HRV (with all measurement methods, including DFA) decreases immediately 
after surgery and recovers gradually within 6-12 months (Kuo et al. 1999; Laitio et 
al. 2006). Another study (Lakusic et al. 2013) showed that decreased HRV persisting 
after CABG was associated with higher mortality during a mean follow-up of three 
years but this is contradicted by previous reports (Milisevic et al. 2004; Stein et al. 
2004). Nevertheless, impaired HRV is associated with postoperative myocardial 
ischaemia and prolonged need of intensive care following CABG (Laitio et al. 2000; 
Laitio et al. 2002). Furthermore, of the nonlinear measurements of HRV, particularly  
DFA has been shown to be superior to time and frequency domain methods (Laitio 
et al. 2000; Wu et al. 2005).  
Impaired nocturnal HRV has also been shown to promote postoperative myocardial 
ischaemia in patients undergoing surgery due to hip fracture, emphasising the 
cardiovascular risk associated with sleep (Laitio et al. 2004). Investigations on long-
term outcome following non-cardiac surgery have shown that depressed HRV 
measured perioperatively is an independent predictor of one-year mortality 
(Filipovic et al. 2003).  
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2.6.4 Open issues 
Analysis of HRV provides means for evaluating autonomic dysfunction that is 
essential in the development of cardiovascular disease. However, the clinical 
feasibility of HRV to guide clinical decisions is limited because the assessment of 
HRV from 24-hour recordings is time-consuming and there are no reliable tools for 
automatic editing of data and calculation of HRV parameters. Furthermore, several 
other factors than atherosclerosis affect autonomic regulation of heart rate and 
circulation. Although diabetic autonomic neuropathy may act as a confounder and 
actually decrease the association of depressed HRV with mortality (Stein et al. 
2004), other studies have shown that autonomic neuropathy, as reflected by impaired 
HRV, independently predicts post-AMI overall mortality in diabetic patients 
(Wheeler et al. 2002; Whang et al. 2003). Since untreated OSA increases 
sympathetic activation and is associated with hypertension, it can be expected to 
cause significant HRV alterations that could potentially be reversed with CPAP. 
More data are needed to confirm the independent predictive value of HRV alterations 
in an individual patient and in different disease states or pathophysiological 
conditions.  
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3. AIMS OF THE STUDY 
This study aimed at finding clinical risk stratification tools for patients with PAD 
undergoing surgical revascularisation. To achieve this, prevalence and clinical 
significance of OSA were determined in consecutive patients that were referred to 
sub-inguinal vascular surgery due to lower limb ischaemia. In addition, 
characteristics of sleep-time HRV were measured. The specific objectives were as 
follows: 
 
 
1. Determine the prevalence and clinical characteristics of OSA in the study 
population by performing a preoperative PSG to all enrolled patients.  
 
2. Establish the predictive value of OSA for major postoperative adverse events 
following vascular surgery. 
 
3. Assess the characteristics of HRV in patients with PAD in different sleep 
stages, compared to healthy controls, and the impact of HRV alterations on 
postoperative outcome  
 
4. Explore the effect of OSA and its severity on cardiac autonomic regulation 
and HRV in the study subjects.   
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4. MATERIALS AND METHODS 
4.1 Study design and subjects 
The BAROSLEEP trial (ClinicalTrials.gov identifier NCT00712946) was designed 
to increase our understanding of the pathophysiology underpinning the poor long-
term outcome of PAD patients. Between April 2006 and December 2011, 
consecutive patients aged 40 years or more and scheduled for elective sub-inguinal 
revascularisation in the Turku University Hospital Department of Vascular Surgery 
were asked to participate in the study and undergo preoperative polysomnography 
with HRV measurements. Types of vascular surgery included femoral cross-over, 
endarterectomy and femoro-popliteal bypass with autologous vein or prosthetic 
graft. Criteria for exclusion were pre-existing OSA syndrome, clinical heart failure, 
atrial fibrillation (HRV analysis requires sinus rhythm), non-cooperation 
(immobility, dementia or otherwise insufficient cognitive function), end-stage renal 
disease, coronary bypass within 3 years or other major surgery within 3 months prior 
to enrolment. Altogether, 301 patients were screened, 156 of which were excluded 
due to the criteria mentioned above. Of the 145 eligible patients 59 did not consent 
and were excluded. Of the 86 enrolled patients, two more had to be excluded due to 
PSG failure. Finally, 84 patients completed the follow-up; the flow chart detailing 
the screening and exclusion of patients according to each criterion is shown in Figure 
1. In addition, a control group was recruited (by an in-hospital advertisement) from 
22 healthy volunteers without hypertension, diabetes or any cardiovascular disease. 
The study was approved by the Ethics Committee of the Hospital District of 
Southwest Finland, Turku, Finland (statement and approval number 404/2005) and 
subjects willing to participate signed a written informed consent. Postoperative 
follow-up was planned to continue until at least one year had passed from the surgery 
of the last recruited patient. 
4.2 Data collection and analysis 
4.2.1 Clinical evaluation 
The enrolled patients underwent a detailed clinical evaluation. Medical history was 
taken; coronary artery disease and hypertension were considered to be present if 
previously diagnosed, i.e. no specific diagnostic tests were made for these. 
Echocardiography was performed routinely; patients with a mildly decreased LVEF 
(40-50%) but without clinical heart failure were not excluded. The 2-hour glucose 
tolerance test was done for those without pre-existing diabetes mellitus and the 
diagnosis of diabetes, impaired fasting glucose or impaired glucose tolerance was 
made according to the current criteria (American Diabetes Association 2015). 
Venous blood samples were taken to determine lipid profile (unless available from 
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hospital records). Waist circumference was also measured (increased when ≥88 cm 
in females, ≥103 cm in males) and used together with hypertension, impaired glucose 
metabolism, decreased HDL (<1.03 mmol/l in males, <1.3 mmol/l in females) or 
elevated triglycerides (≥1.7 mmol/l) to diagnose metabolic syndrome, i.e. if three 
more of the above criteria were met (Grundy et al. 2005). ABI and toe pressures were 
measured to assess lower limb circulation; the latter was used in diabetic patients 
with unreliably high ABI due to mediasclerosis. 
 
 
 
 
Figure 1. Patient recruitment from screening to endpoint analysis. CABG = Coronary artery 
bypass grafting, Inability to co-operate = immobility, dementia or otherwise insufficient 
cognitive function, OSA = Obstructive sleep apnoea, PSG = Polysomnography. (Modified 
from original publication II) 
301 patients screened
(age >40 years,
sub-inguinal surgery scheduled)
145 patients
were eligible 
for the study
86 patients 
consented 
and 
underwent 
PSG
PSG and surgery 
successful in 84 
patients. None lost 
to follow-up
84 patients
included in the 
final analyses
2 patients operated 
but excluded due 
to unreadable PSG.
59 patients 
refused to 
participate
156 patients 
excluded due to 
exclusion 
criteria
Previous OSA: 12
CABG, other major 
surgery: 4
End-stage renal 
disease: 7
Atrial fibrillation:71
Inability to co-
operate: 62
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4.2.2 Sleep studies 
4.2.2.1 PSG recordings and analyses 
An overnight PSG (Embla/Somnologica 3.0; MedCare, Reykjavik, Iceland) was 
performed preoperatively for all the included patients and healthy controls. The PSG 
setting included four EEG channels, two EOG channels, EMG and ECG. Respiratory 
flow was measured with a nasal cannula connected to a pressure transducer. Two 
pulse oximeters were used, one to record arterial oxyhaemoglobin saturation and 
another for plethysmographic pulse wave. The PSG recordings were analysed 
immediately before the investigators had any knowledge of possible adverse events. 
Sleep stages were scored according to the standard rules for sleep scoring 
(Rechtschaffen & Kales 1968) and arousals from sleep were identified using 
appropriate guidelines (Sleep Disorders Atlas Task Force of the American Sleep 
Disorders Association 1992). A cessation of breathing for at least ten seconds was 
required to score an apnoea and the definition of hypopnoea was a tidal volume  
reduction of >50% combined with oxyhaemoglobin desaturation ≥4% (both 
required). The AHI was calculated and the oxyhaemoglobin desaturation index 
(ODI) was also determined as the number of desaturations (≥4%) per hour of sleep 
(American Academy of Sleep Medicine Task Force 1999). The ODI was used 
instead of the AHI to diagnose OSA in patients with unanalysable respiratory flow 
due to detached nasal cannula. Arousal index was determined as the number of 
arousals per hour of sleep. PTT was calculated from the R-peak of the ECG to the 
peak of the peripheral pulse wave; the same device was used to monitor both the 
ECG and plethysmography. The respiratory swing observed in the PTT was 
displayed graphically by the analysis software (WinCPRS 1.1.6.0 for Windows; 
Absolute Aliens Inc., Turku, Finland) and used to differentiate obstructive and 
central apnoea from each other (each apnoea analysed separately on the PTT 
timeline), as described in detail elsewhere (Argod et al. 1998; Argod et al. 2000). 
4.2.2.2 Classification of OSA severity 
The different classifications of OSA severity that were used in the sub-studies are 
summarised here and the corresponding original publication is referred to with its 
Roman numeral.  
I. For the first study determining the prevalence and characteristics of 
OSA in patients with PAD, OSA was diagnosed with an AHI ≥5/hour 
and its severity was graded as mild (AHI 5-15/hour), moderate (AHI 15-
30/hour) or severe (≥30/hour) as is the common classification in clinical 
use (American Academy of Sleep Medicine Task Force 1999). 
II. In the second study assessing the association of OSA with postoperative 
adverse events, a dichotomic threshold of AHI ≥20/hour indicating 
significant OSA was used.  This was based both on previous literature 
(Martínez-García et al. 2009; Gooneratne et al. 2011) and statistical 
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analyses performed with this study population. Preliminary analyses 
were first performed with increments in the AHI of 10/hour, i.e. the 
study sample was divided into patients with AHI 0–10/hour, 10–
20/hour, 20–30/hour and >30/hour. The latter three groups were then 
compared to the first. With the first two categories appearing 
insignificant and the last two the most likely predictors of adverse events 
in terms of hazard ratio (see Results section for details), these pairs of 
patient groups were combined to determine the AHI≥20/hour as cut-off. 
III. In the third study dealing with the effect of HRV on postoperative 
outcome, the same dichotomic cut-off was first used. This was done 
partly to simplify the analysis but also to elucidate the pathophysiology 
association of OSA with adverse outcome, i.e. to determine whether 
OSA per se (with the same threshold) is associated with decreased HRV 
and impaired autonomic control of heart rate. Furthermore, to evaluate 
the evolution of the different HRV parameters as the AHI and severity 
of OSA progress, the study population was also divided into subclasses 
with equal increments in the AHI with steps of 10 events/hour (i.e. AHI 
0–10/hour, 10–20/hour, 20–30/hour and >30/hour). 
4.2.2.3 Sleep questionnaires 
Sleep history was taken; both the Epworth Sleepiness Scale (ESS) and the Berlin 
Questionnaire (BQ) were performed to assess EDS, snoring and other symptoms of 
OSA. An ESS score of ≥10 indicated EDS (Johns 1991) and two or three positive 
categories in the BQ showed a strong suspicion of OSA (Netzer et al. 1999). EDS 
was handled also as a categorical variable, in addition to the ESS score. If OSA was 
diagnosed in the PSG, scores from the questionnaires were reviewed and the study 
subjects were offered the possibility to be referred to a pulmonologist for 
consideration of CPAP therapy. The surveillance of the outcome of these 
consultations was not included in the follow-up protocol.  
4.3 HRV analysis 
4.3.1 Acquisition, reviewing and editing of ECG data 
The ECG data was transferred from a Datex-Ohmeda scanner to a laptop computer 
and the files were converted to be readable with the analysis software (WinCPRS; 
Absolute Aliens Inc., Turku, Finland) HRV was analysed during continuing sleep in 
10-minute epochs; the sleep stage without awakenings was required. HRV was also 
analysed during 10-minute wake periods in the evening and in the morning, 
separately. The ECG was then carefully reviewed and epochs with ectopic beats 
more than 10 % were excluded. All other ectopic beats were interpolated, i.e. the 
extrasystolias were removed and replaced in the exact middle of the preceding and 
following sinus beats. This  method  has  been used earlier and is considered reliable  
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when less than 10 % of total beats are interpolated (Huikuri et al. 1996). The 
stationarity of the data was tested with the StatAvF algorithm of the analysis software 
(see supplementary files in original publication III for details). 
4.3.2 HRV parameters 
NNI between normal (or interpolated) R-peaks of the QRS complex of the ECG was 
used to analyse HRV parameters in the time and frequency domain. The statistical 
time domain measurements that were performed included standard deviation of NNI, 
root mean square of the sum of successive differences (RMSSD) between adjacent 
NNI (i.e. beat-to-beat variability) and proportion of NNI >50 ms (pNN50). The 
frequency domain measurements included ULF, VLF, LF and HF power as well as 
the LF/HF ratio. The normalised units of LF and HF (nLF and nHF, respectively) 
were also measured. Of the non-linear measurements, sample entropy was calculated 
and fractal characteristics of the NNI time series were measured using the scaling 
exponent alpha 1 determined by DFA (see 2.6.2.2 in Review of the Literature).  
4.4 Follow-up and definition of outcome 
After the operation, the patients were followed at the surgical ward and cardiac 
troponin T (cTn-T) was routinely measured on three consecutive postoperative days. 
Any elevation of cTn-T over the threshold of 0.03 mg/ml indicated postoperative 
AMI. After hospital discharge, the patients were routinely seen by a surgeon and one 
of the investigators at the surgical outpatient ward six weeks and one year 
postoperatively. Later, the patients were contacted by phone at least once per year. 
Information of adverse events were obtained by interviewing the patients and further 
details were acquired from their medical records. In terms of long-term outcome, 
MACCE was used as a combined endpoint. MACCE included cardiac death, AMI, 
any need for coronary revascularisation (CABG or coronary angioplasty, excluding 
elective angiography not ending in angioplasty), unstable angina pectoris requiring 
hospitalisation and stroke (ischaemic or haemorrhagic). AMI was determined by the 
third universal definition (Thygesen et al. 2012). 
4.5 Statistical analysis 
4.5.1 Calculation of sample size 
Based on a pre-study power analysis, the original intention was to recruit a total of 
100 patients in order to evaluate the possible preoperative predictive value of altered 
short-term fractal heart rate variability (i.e. scaling exponent alpha 1) in different 
sleep stages for postoperative MACCE in PAD patients. According to earlier studies 
approximately one third and up to 50% of PAD patients should develop a myocardial 
infarction (i.e. cTn-T ≥0.03 mg/ml, the detection threshold when the study 
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procedures were carried out) within three postoperative days and the five-year 
mortality in these patients was expected to be approximately 30 % (Conte et al. 2001; 
Landesberg et al. 2003; Levy et al. 2011). Power was fixed to 85 % and significance 
level to 0.05 in the calculations. The calculated total number of patients varied 
between 80 and 100, depending on the incidence of myocardial infarction between 
30-50 % to reveal statistically significant differences. Mainly due to exclusion 
criteria and a large number of patients not consenting, the enrolment was difficult 
and slow. Therefore, it was decided to stop recruitment and perform survival analysis 
after the 86th patient had gone through a follow-up of at least one year. 
4.5.2 Probability of OSA 
After OSA was diagnosed and classified, the confidence interval of its prevalence 
was determined by binomial distribution. Spearman’s correlation coefficient was 
used to test for the interdependence of the AHI and ODI in this study population. 
The association of each baseline clinical characteristic (smoking status, metabolic 
syndrome, BMI, waist circumference, diabetes, hypertension, coronary artery 
disease, stroke history, LVEF, LDL, HDL, HDL/cholesterol ratio, triglycerides, 
ABI, toe pressure, PAD duration, critical ischaemia) and sleep variable (BQ and ESS 
score, EDS, arousal index, mean and lowest nocturnal oxyhaemoglobin saturation, 
cumulative time below 90 % saturation) with the severity of OSA was tested using 
cumulative logistic regression models. Because the study sample had few patients 
having no OSA at all, the association of the predictors with the prevalence of OSA 
in general was not tested separately. Instead, the severity of OSA (including patients 
with no OSA) was used as an ordinal dependent variable. After excluding variables 
with a significance of association of P >0.1, the independent predictive value of each 
remaining variable was determined using a stepwise multivariate analysis, adjusted 
for age and gender. The cumulative odds ratio (OR) with 95 % confidence interval 
(CI) predicting the worsening of OSA and corresponding to a change equal to the 
standard deviation of each predictor was then calculated. 
4.5.3 OSA and other predictors of MACCE 
The preliminary analyses were performed as described in section 4.2.2.2, item II. 
Due to sample size, very similar hazard ratios and confidence intervals it was deemed 
viable to combine the groups with AHI 20-30 and AHI >30. That being said, the AHI 
≥20 threshold for significant OSA was determined as a post hoc decision based both 
on previous literature and observations made in this study. A Kaplan–Meier plot was 
then used to show the impact of significant OSA on event-free survival. Two-tailed 
P-values of <0.05 were considered statistically significant. 
Univariate Cox regression analysis was used first to determine variables associated 
with MACCE. All clinical variables recorded at baseline were tested separately (age, 
gender, smoking status, PAD duration, stroke history, coronary artery disease, 
metabolic syndrome, diabetes, hypertension, critical ischaemia, ABI, BMI, waist  
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circumference, LVEF, lipid values). Of the sleep variables, significant OSA (AHI 
≥20/hour), central sleep apnoea, arousal index, mean (SaO2 Mean) and lowest (SaO2 
Nadir) oxygen saturation, time below 90% saturation (SaO2 T90), ESS score and 
pathological BQ score as a cathegorical variable were tested. In these analyses, the 
duration of PAD history was used as a categorical variable (0–3 years and ≥4 years, 
see below for details). ODI was excluded from the final regression model because of 
its close dependence of the AHI (and was also used to define hypopnoea) to avoid 
the multicollinearity problem that would undo the default assumptions of the 
multivariate analysis (see Results section for details). Variables significantly 
associated with the occurrence of MACCE in the univariate analysis were included 
in a multivariate Cox regression analysis using a stepwise selection method 
(inclusion criteria P <0.05 and exclusion criteria P ≥0.05). The proportional hazards 
assumption in Cox models was tested with Martingale Residuals and graphically 
using the plots of the logarithm of the negative logarithm (log(-log(S)) of the 
estimated survival function against survival time; the proportional hazards 
assumptions were met. The results are presented using hazard ratio (HR) with 95% 
CI.  
In the regression models, the duration of PAD was divided into subclasses and 
handled as a categorical variable as follows: 
1. PAD_year2, 1 = 0−1  years, 2 = 2−16 years 
2. PAD_year3, 1 = 0−2  years, 2 = 3−16 years 
3. PAD_year4, 1 = 0−3  years, 2 = 4−16 years 
4. PAD_year5, 1 = 0−4  years, 2 = 5−16 years 
Of these, the last three (i.e. PAD duration of <3 years, <4 years or <5 years) were 
significant predictors (but not <2 years). The four-year cut-off for PAD duration was 
finally chosen because it had the most significant P-value and highest hazard ratio 
(P=0.030, HR 3.32, 95% CI 1.13–9.79) in the univariate analysis, compared to the 
alternatives. This threshold was also deemed clinically relevant.  
4.5.4 Associations of HRV alterations with OSA and MACCE 
The HRV parameters were analysed from 1–5 different 10-minute epochs (per 
subject) of S2 sleep, 1–3 epochs of REM sleep and 1–2 epochs of S3-4 sleep. Results 
obtained from the same sleep stage were then averaged. Wakefulness periods in the 
evening and in the morning after awakening were analysed separately; these results 
were not averaged. Finally, analyses with all sleep stages (S2, S3-4, REM) combined 
were performed from 1–7 averaged epochs (per study subject, some of which had 
only one analysable 10-minute sample from one sleep stage). 
One-way analysis of variances (ANOVA) was used to test for differences in 
parameters. Non-normally distributed variables were log-transformed (natural 
logarithm) and the requirement for normal distribution was met after the 
transformation. Dunnett’s post hoc adjustment for multiple comparisons was used in 
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the ANOVA model. An analysis of covariances (ANCOVA) adjusted for age, body 
mass index, coronary artery disease and PAD history of <4 years was then performed 
to test for an independent association of significant OSA (AHI ≥20/hour) and 
MACCE (healthy controls not included) with each HRV parameter. In the analyses 
with all sleep stages combined, ANOVA and ANCOVA models were also used to 
test for independent association of the HRV parameters with worsening OSA (AHI 
10-20/hour, AHI 20-30/hour and AHI >30/hour with AHI <10/hour used as a control 
group) and MACCE.  
4.5.5 Other statistical procedures 
In the analyses regarding the effect of significant OSA (AHI ≥20/hour) on the 
incidence of MACCE, the statistical differences in each clinical (demographics, 
prevalence of co-morbidities, ABI and LVEF) and sleep variable (ESS and BQ 
scores, prevalence of EDS, PSG parameters) between patients with and without 
significant OSA were determined using the Mann–Whitney U-test for continuous 
variables and Fisher’s exact test for categorical variables. The Shapiro–Wilk test was 
used to test for normal distribution of data.  
In the HRV analyses, patient groups with and without MACCE, and patients with 
and without significant OSA (AHI >20/hour) were compared to healthy controls 
with ANOVA for normally distributed variables; Dunnett’s post hoc correction was 
used to adjust for multiple comparisons. Again, non-normally distributed variables 
were log-transformed before any of these analyses were performed; Kruskal-
Wallis’s test and Mann-Whitney’s U-test with Bonferroni’s adjustment for multiple 
comparisons were used to test for differences in variables that were still skewed after 
log-transformation. Exact Fisher’s test was used to test for differences in categorical 
variables between patient groups. P-values below 0.05 were considered statistically 
significant. In the tabular presentation, data is described using mean (standard 
deviation, SD) for normally distributed variables and median [interquartile range, 
IQR] for non-normally distributed variables. 
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5. RESULTS 
5.1 Patient demographics and clinical characteristics 
All of the included 84 subjects (62 % male, aged 67 ± 9 years) were outpatients, 
living independently and some of them were still working actively. The average 
duration of PAD from diagnosis to enrolment was approximately four years and 31 
patients (37 %) had PAD history longer than four years and the mean ABI was 0.55. 
Besides PAD, the majority had other manifestations or risk factors of cardiovascular 
such as coronary artery disease (37 %), stroke history (17 %), diabetes (43 %) or 
hypertension (83 %). While obesity was in a minority as 14 patients (17 %) had a 
BMI of 30 kg/m2 or greater (average BMI 26 kg/m2), especially female patients had 
an elevated waist circumference (males 101 ± 9 cm, females 102 ± 12 cm) and 
metabolic syndrome was diagnosed in 51 (61 %) patients. LVEF decreased 
significantly in parallel with worsening OSA despite remaining in the normal range; 
only four patients had a slightly abnormal systolic function (LVEF 40-50 %) without 
clinical heart failure. There was no difference between patient groups (according to 
severity of OSA or incidence of MACCE) in the usage of beta-blockers or other 
pertinent long-term medications (antihypertensives, antithrombotic agents, opioids, 
benzodiazepines). Antihypertensive medication was used by 91 % and 23 % had 
three or more antihypertensives. Acetylsalicylic acid was used by 83 % and 62 % 
were on statins. 
The demographic features and baseline clinical characteristics of patients 
participating in the study are summarised in Table 1. Subjects that were otherwise 
eligible but refused their consent were significantly older than those who were 
enrolled and completed the follow-up (71 vs. 67 years; P = 0.02). These two groups 
did not differ in any other clinical characteristics that were available from those 
refusing to participate (gender, smoking status, BMI, diabetes, hypertension, CAD, 
stroke history, ABI, PAD duration, presence of critical ischaemia). 
5.2 Demographic and clinical characteristics of controls 
One control subject had to be excluded due to failed PSG. Of the remaining 21 
controls, there were three subjects with mild OSA, three with moderate OSA and 
three with severe OSA. Thus, the prevalence of OSA in this supposedly healthy 
group was 43 %. It was decided to include the three subjects with mild OSA (having 
the AHI in the range of 5 – 9/hour) and to exclude the ones with moderate or severe 
OSA due to the potiential effect of OSA on HRV. Thus, 15 controls were included 
in the HRV analyses. The enrolled patients were older than the control subjects (67 
vs. 63 years; P = 0.049). There was also a higher BMI (27 vs. 24 kg/m2; P = 0.0004), 
lower LVEF (63 % vs. 70 %; P = 0.006) and more common male gender (67 vs. 33 
%; P = 0.0496) among the included patients than controls. 
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Table 1. Baseline characteristics according to severity of obstructive sleep apnoea (OSA). 
 All patients 
n = 84 
No OSA 
n = 12 
Mild OSA 
n = 25 
Moderate OSA 
n = 23 
Severe OSA 
n = 24 
Age, years 67 (9) 65 (7) 65 (10) 69 (8) 70 (8) 
Male, n 52 (62) 7 (58) 11 (44) 14 (61) 20 (83) * 
Smoker, n 32 (38) 7 (58) 12 (48) 5 (22) 8 (33) 
Metabolic sdr., n 51 (61) 5 (42) 14 (56) 15 (65) 17 (71) 
BMI, kg/m2 27 (4) 27 (3) 27 (4) 26 (5) 28 (4) 
Waist circumference, cm     
      Male 101 (9) 102 (6) 98 (11) 102 (12) 101 (6) 
      Female 102 (12) 105 (16) 105 (11) 97 (12) 98 (15) 
Diabetes, n 36 (43) 6 (50) 12 (48) 11 (48) 7 (29) 
Hypertension, n 64 (76) 8 (67) 16 (64) 20 (87) 20 (83) 
CAD, n 31 (37) 3 (25) 8 (32) 11 (48) 9 (38) 
Stroke, n 9 (11) 4 (33) 2 (8) 1 (4) 2 (8) 
LVEF, % 63 (8) 68 (5) 66 (7) 63 (8) 59 (9) ‡ 
Cholesterol, mmol/L 4.3 (1.0) 4.3 (1.2) 4.3 (0.9) 4.5 (1.0) 4.3 (1.1) 
      LDL, mmol/L 2.2 (0.8) 2.1 (0.9) 2.0 (0.8) 2.3 (0.5) 2.2 (1.0) 
      HDL/Chol, % 34 (10) 37 (13) 38 (9) 31 (8) 32 (10) † 
      TGL, mmol/L 1.4 [1.2] 1.0 [1.2] 1.4 [1.0] 1.6 [1.2] 1.5 [1.3] 
ABI, ratio 0.6 (0.2) 0.5 (0.2) 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 
Toe pressure, mmHg 51 (24) 44 (25) 56 (16) 49 (16) 52 (32) 
PAD history, years 2 [5] 2 [5] 3 [4] 4 [6] 4 [6] 
Critical ischaemia, n 11 (13 ) 4 (33) 1 (4) 2 (9) 4 (17) 
Data are number (percentage) of patients, mean (standard deviation) or median [interquartile range]. ABI = Ankle-
brachial index, BMI = Body mass index, CAD = Coronary artery disease, HDL/Chol = High density 
lipoprotein/Total cholesterol ratio, LDL = Low density lipoprotein, LVEF = Left ventricular ejection fraction, 
Metabolic sdr. = Metabolic syndrome. PAD history = Time from the onset of peripheral arterial disease, TGL = 
Triglycerides. The significance of association with the severity of OSA was tested with univariate cumulative 
logistic regression analysis (analysed with n = 82 for original publication I); p-values reflect the association of the 
variable with the severity of OSA. *: p = 0.02; †: p = 0.03; ‡: p = 0.002. (Modified from original publication I) 
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5.3 Prevalence and clinical characteristics of OSA 
OSA of any severity (AHI ≥5/hour) was detected in 72 out of 84 patients (overall 
prevalence of 86 %; 95 % CI 76 – 92 %). In the whole study population, 25 (30 %) 
had mild OSA (AHI 5 - 15/hour), 23 (27 %) had moderate OSA (AHI 15 - 30/min) 
and 24 (29 %) had severe OSA (AHI ≥30/hour). In other words, OSA was moderate 
or severe in over one half of all patients and in approximately two thirds of the 
patients with OSA. Baseline clinical characteristics according to this classification 
of OSA severity are shown in Table 1. ODI (mean 23/hour, median 17/hour, IQR 
26) correlated very closely with the AHI (mean 23/hour, median 18/hour, IQR 26) 
in the whole study population (Spearman’s correlation coefficient r=0.93). The type 
of apnoea was predominantly obstructive despite a relatively high percentage of 
central episodes (mean 19 %, median 22 %, IQR 13) but the central apnoea index 
(mean 5/hour, median 4/hour, IQR 5) in the whole study population was low. The 
proportion of central apnoea did not differ between patients using opioids at baseline 
compared to those who did not (21 % vs. 23 %). 
As expected, the arousal index and SaO2 T90 increased with worsening OSA. SaO2 
Nadir was also worst in patients with severe OSA but there was no difference in 
SaO2 Mean across the OSA severity categories. The sleep variables are summarised 
in Table 2. 
In general, the patients diagnosed with OSA in this study were either minimally 
symptomatic or completely asymptomatic, i.e. they did not suffer from sleepiness. 
The ESS scores were low as a whole (mean 5, median 4, total range 0 – 17) and did 
not increase with worsening OSA; EDS (ESS score > 10) was evident in a total of 
eight patients (11 % of all patients with OSA), five of which had only mild OSA 
while there were two patients with moderate OSA and one with no OSA. Notably, 
none of the patients with severe OSA had EDS. Snoring was still common along 
with general fatigue (but without excessive sleepiness) which was observed in the 
BQ scores. Two or more positive BQ categories seemed to be more common in 
patients with OSA than in those without and especially in moderate or severe OSA 
but the difference was not significant.   
5.3.1 Variables associated with the presence and severity of OSA 
In the cumulative logistic regression analysis (performed with the 82 patients that 
were included in original publication I), LVEF and HDL/Chol, SaO2 Nadir and 
arousal index along with male gender and age were the only variables associated 
with the severity of OSA. The presence or severity of OSA was not related to obesity, 
metabolic syndrome or diabetes. Hypertension seemed to be more prevalent in 
patients with moderate or severe OSA but the difference did not reach statistical 
significance. The AHI did not correlate to the severity of atherosclerosis in terms of 
ABI and toe pressures or presence of other cardiovascular manifestations (coronary 
artery disease, stroke history). Arousal index, SaO2 Nadir and SaO2 T90 saturation 
excluded were considered inherently associated with OSA and were thus excluded 
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from the multivariate model. In the multivariate analysis adjusted with age and 
gender, LVEF (cumulative OR 2.3, 95% CI 1.4 – 3.8; P = 0.002, corresponding to a 
decrease equal to SD of 8 %-point) and HDL/Chol (cumulative odds ratio 1.7, 95% 
CI 1.1 – 2.7; P = 0.03, corresponding to a decrease equal to SD of 10 %-point) 
remained significantly associated with the severity of OSA. Decreasing percentages 
in both parameters were associated with worsening OSA so that the OR values reflect 
the odds of a patient having more severe OSA compared to lower OSA categories 
(no OSA handled as one of the categories). 
 
 
 
Table 2. Sleep variables and sleep times according to the severity of OSA 
 No OSA 
n = 12 
Mild OSA 
n = 25 
Moderate OSA 
n = 23 
Severe OSA 
n = 24 
BQ 2-3, n 4 (33) 10 (40) 12 (52) 11 (46) 
ESS score, range 5 (1-12) 6 (0-17) 6 (0-11) 4 (0-10) 
EDS (ESS >10), n 1 (8) 5 (20) 2 (9) 0 (0) 
Arousal index, 1/h 13 (7) 17 (9) 22 (9) * 27 (9) ‡ 
CSA, % 23 (12) 22 (11) 23 (6) 24 (8) 
SaO2 Nadir, % 88 (3) 85 (5) 83 (6) * 81 [14] † 
SaO2 Mean, % 93 (2) 93 (2) 95 [3] 94 [4] 
SaO2 T90, minutes 0 [4] 3 [12] 4 [9] 14 [97] * 
TST, minutes 293 (80) 327 (83) 269 (80) 261 (87)  
S1 sleep, minutes 32 (22) 36 (20) 46 (30) 66 (31) 
S2 sleep, minutes 184 (60) 214 (62) 165 (61) 143 (66) 
S3-4 sleep, minutes 34 (23) 26 (32) 24 (25) 21 (20) 
REM sleep, minutes 42 (25) 50 (35) 34 (19) 31 (29) 
Data are number (percentage) of patients, mean (standard deviation) or median [interquartile range] unless otherwise 
stated. BQ 2-3 = 2 or 3 positive Berlin Questionnaire categories indicating high risk of OSA, CSA = Central sleep 
apnoea percentage, EDS = Excessive daytime sleepiness, ESS = Epworth sleepiness scale, REM = Rapid eye 
movement, SaO2 Mean = Average oxyhaemoglobin saturation, SaO2 Nadir = Lowest oxyhaemoglobin saturation, 
SaO2 T90 = Cumulative time below 90% oxyhaemoglobin saturation. The significance of association with the 
severity of OSA was tested with univariate cumulative logistic regression analysis (analysed with n = 82 for original 
publication I, sleep times not included); p-values reflect the association of the variable with the severity of OSA. *: 
p = 0.02; †: p = 0.0001; ‡: p < 0.0001. (Modified from original publication I) 
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5.4 Endpoints during follow-up 
After a median follow-up of 52 months (ranging from 14 to 84 months), eighteen 
patients had died (all-cause mortality 21 %). Nine of these were cardiac deaths, two 
were fatal cerebrovascular events (one ischaemic and one haemorrhagic stroke), and 
seven were due to other causes (cancer, septicaemia, liver cirrhosis, pulmonary 
fibrosis, alcoholism). Altogether, 23 patients suffered a MACCE and the first event 
of each patient occurred after a median of 16 months (ranging from 0 to 75 months) 
after the index surgery. Of short-term events, one AMI and one cardiac death 
occurred within thirty days after the surgery in addition to one perioperative 
myocardial infarction (elevated cTn-T) within three days after surgery. Altogether, 
seven events and three deaths took place within the first postoperative year (one-year 
mortality 4 %). One-year mortality for significant OSA was 8 % and all patients 
dying within one year had AHI ≥20/hour. A summary of all endpoints, including 
limb complications (e.g. graft occlusion, amputation) is shown in table 3. 
 After a follow-up of five years (no regression analysis performed), 21 patients 
had died (of any cause), yielding a five-year mortality of 25 %. Of these, 14 had 
significant OSA (five-year mortality 36 % in patients with AHI ≥20/hour vs. 8 % in 
those without).   
 
 
 
Table 3. Major endpoints according to severity of obstructive sleep apnoea. 
 All patients 
n = 84 
AHI <20 
n = 45 
AHI ≥20 
n = 39 
All-cause mortality, n 18 (21) 6 (13) 12 (31) 
Combined MACCE, n 23 (27) 6 (13) 17 (44) † 
Fatal MACCE, n 11 (13) 2 (4) 9 (23) * 
      Cardiac death, n 9 (11) 1 (2) 8 (18) * 
      Stroke, n 2 (2) 1 (2) 1 (2) 
Non-fatal AMI, n 7 (8) 2 (4) 5 (13) 
Coronary revascularisation, n 4 (5) 2 (4) 2 (5) 
Unstable angina pectoris (hospitalisation), n 1 (1) 0 (0) 1 (3) 
Limb complication, n 22 (26) 10 (22) 12 (31) 
      Amputation, n 3 (4) 0 (0) 3 (8) 
      Assisted patency (PTA included), n 19 (23) 10 (22) 9 (23) 
Data are number (percentage) of patients. AMI = Acute myocardial infarction, MACCE = Major adverse 
cardiovascular or cerebrovascular event, PTA = Percutaneous transluminal angioplasty. P-values were calculated 
using univariate Cox regression analysis. *: P < 0.05, †: P < 0.01 (between patients with and without AHI ≥20/hour) 
(Reproduced from original publication II) 
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5.5 Predictors of MACCE 
In the univariate Cox regression, three different categories of PAD duration (i.e. <3 
years, <4 years or <5 years) were significant predictors (but not <2 years). The four-
year threshold for PAD duration had the most significant P-value and highest hazard 
ratio (P = 0.03, HR 3.32, 95% CI 1.13 – 9.79) in the univariate analysis, compared 
to the alternatives and was chosen as threshold (see Materials and Methods 4.5.3). 
AHI was significantly higher in patients suffering a MACCE (P = 0.049). Other 
significant predictors were age (P = 0.03), pre-existing coronary artery disease (P = 
0.004), PAD history of <4 years (as above), SaO2 Nadir (P = 0.03), HDL (P = 0.04) 
and HDL/Chol (P = 0.02). In the analyses to determine a threshold in the AHI (see 
Materials and Methods 4.2.2.2), AHI 20-30 (HR 3.0, 95% CI 0.9 - 10.5, P = 0.08) 
and AHI >30 (HR 3.4, 95% CI 1.0 - 11.3, P = 0.04) appeared as the best predictors 
of MACCE with other significant factors included; the AHI 0-10/hour and AHI 10-
20/hour seemed to be insignificant. When the cut-off of AHI ≥20/hour was chosen, 
it appeared as the most significant predictor of MACCE (P = 0.003).  
Variables that were shown to be significant predictors of MACCE in the univariate 
analysis were included in the multivariate Cox regression model. ODI was left out 
of the regression analyses to avoid multicollinearity because of its close associaton 
with the AHI. In addition, SaO2 Nadir and HDL were excluded as inherently related 
to significant OSA and HDL/Chol, respectively (HDL/Chol chosen over HDL as the 
more significant predictor). AHI ≥20/hour (HR 5.1, 95% CI 1.9 – 13.9; P = 0.001) 
and pre-existing coronary artery disease (HR 4.4, 95% CI 1.8 – 10.6; P = 0.001) 
remained as strong independent predictors. PAD history of <4 years (HR 3.8, 95% 
CI 1.3 – 11.5); P = 0.02) and HDL/Chol (HR 0.95 per 1% increase 95% CI 0.90 – 
1.00; P = 0.048) also predicted MACCE. To test the usefulness of ODI alone, a 
multivariate analysis was also done with the AHI replaced by the ODI. With the 
corresponding cut-off, ODI ≥20/hour was also an independent predictor of MACCE 
(HR 7.0, 95% CI 2.4 - 20.4, p=0.0004). Coronary artery disease, PAD history 4 
years and HDL/Chol ratio also remained significant with similar P-values and 
confidence intervals. 
A Kaplan-Meier plot visualising the effect of significant OSA (AHI ≥20/hour) on 
event-free survival is shown in Figure 2. None of the pertinent medications, 
including beta-blockers, had a significant association with outcome. All factors that 
significantly influenced the occurrence of MACCE in the univariate or multivariate 
analyses are summarised in table 4. 
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Figure 2. Survival plot for freedom from major adverse cardiovascular and cerebrovascular 
events according to severity of obstructive sleep apnoea based on the threshold of ≥20/hour 
in the apnoea-hypopnoea index (AHI). (Modified from original publication II)  
 
Table 4. Univariate and multivariate predictors of MACCE 
 Univariate analysis  Multivariate analysis  
Predictor HR (95 % CI) P HR (95 % CI) P 
Age (per each year) 1.06 (1.01 – 1.11) 0.028 NS  
SaO2 Nadir (per each %) 0.94 (0.89 – 0.99) 0.029 NS  
Coronary artery disease 3.50 (1.51 – 8.10) 0.004 4.37 (1.81 – 10.6) 0.001 
PAD history <4 years 3.32 (1.13 – 9.79) 0.030 3.80 (1.26 – 11.5) 0.018 
HDL/Chol (per each %) 0.94 (0.90 – 0.99) 0.021 0.95 (0.90 – 1.00) 0.048 
AHI ≥20/hour 4.26 (1.66 – 10.9) 0.003 5.13 (1.89 – 13.9) 0.001 
AHI = Apnoea/hypopnoea index, CI = Confidence interval, HDL/Chol = High density lipoprotein/Total cholesterol 
ratio, HR = Hazard ratio, PAD = Peripheral arterial disease. SaO2 Nadir = Lowest sleep-time oxyhaemoglobin 
saturation. NS = Not selected into the final model. Multivariate analysis was done using stepwise selection method 
(inclusion criteria p < 0.05 and exclusion criteria p ≥ 0.05). (Reproduced from original publication II) 
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5.6 Results of the HRV analyses 
5.6.1 Characteristics of patients and controls 
ECG data eligible for HRV analysis was available from a total of 75 patients (71 in 
S2 sleep, 31 in S3-4 sleep, 58 in REM sleep, 68 in evening wake and 60 in morning 
wake). One patient had analysable ECG only during wakefulness; thus, HRV during 
sleep was available from 74 patients. In other patients, the ECG had excessive 
ectopic beats or was otherwise too disturbed by artefacts. Of the 75 patients, 64 (85 
%) had at least mild OSA and 36 (48 %) had OSA with AHI ≥20/hour. In terms of 
outcome, 22 (29 %) of them suffered a MACCE during the follow-up and 17 (23 %) 
patients died. All of the 15 included controls had analysable ECG data in S2 sleep, 
evening wake and morning wake; nine had data available in S3-4 sleep and 14 in 
REM sleep. The age difference was not significant (67 vs. 63 years; p = 0.08) 
between the patients eligible for the HRV analysis and the included controls (the 
controls were only used as a reference group in the HRV studies). Likewise 
compared, there remained a significantly higher BMI (27 vs. 24 kg/m2; p = 0.009), 
lower LVEF (64 % vs. 70 %; p=0.01) and more common male gender (67 vs. 33 %; 
p = 0.02) among the included patients than in the controls. 
In the StatAvF stationarity testing, 6 % of the epochs chosen for analysis (patients 
and controls combined) were non-stationary (4 % in S2 sleep, 2 % in S3-4 sleep, 9 
% in REM sleep and morning wake, 10 % in evening wake). Thus, most of the data 
were at least moderately stationary; 50 % of all the analysed epochs were considered 
fully stationary (66 % in S2 sleep, 81 % in S3-4 sleep, 38 % in REM sleep, 29 % in 
evening wake and 32 % in morning wake). The amount of fully stationary epochs in 
the included patients was very similar to that of the controls but the controls had even 
less nonstationary segments in all sleep stages and during wakefulness. 
Because of its great significance in predicting adverse outcome, the same cut-off for 
significant OSA (AHI ≥20/hour) was applied to the HRV analyses. The purpose of 
this was to search for possible underlying factors that could explain the said 
association, i.e. whether significant OSA in patients with severe PAD is 
characterised by impaired ANS function and pathological HRV (e.g. sympathetic 
activation and loss of fractal heart rate control). Significant differences between PAD 
patients with and without AHI ≥20/hour, as well as with and without MACCE, 
to  compared  healthy  controls are summarised below. For detailed tabular data of  
each HRV parameter in different stages of sleep and wakefulness, please see  
original publication III.  
5.6.2 Comparisons between patients and controls 
5.6.2.1 Time domain measures 
In general, time domain measures of HRV showed few differences when patient 
groups (with and without AHI ≥20/hour, with and without MACCE) were compared 
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to controls. No differences in any of the time domain parameters were observed 
during evening wakefulness or S3-4 sleep. In the morning, NNI standard deviation 
was lower in patients with AHI ≥20/hour (37 ms vs. 52 ms; P = 0.02 and in those 
who suffered a MACCE (34 ms vs. 52 ms; P = 0.02) than in controls. Maximum 
heart rate during S2 sleep was higher (i.e. lower minimum NNI) in patients with AHI 
≥20/hour (72/min vs. 65/min; P = 0.04). Those suffering a MACCE had a higher 
mean (67/min vs. 58/min; P = 0.02) heart rate during REM sleep. 
5.6.2.2 Frequency domain measures in different sleep stages 
In the frequency domain analyses, LF power was consistently lower in PAD patients 
than in controls. Conversely, HF power was higher in patients than in controls in S2, 
S3-4 and REM sleep as well as during morning wakefulness, except in those who 
suffered a MACCE. In the evening, all patient groups had lower HF power than 
controls. Consequently, the LF/HF ratio was significantly lower in all patient groups 
vs. controls, which was most clearly seen during S2 and REM sleep. None of the 
differences in HF power reached statistical significance but HF was mostly higher 
in all patient groups and in all sleep stages as well as during evening and morning 
wakefulness when measured in normalised units (except during S3-4 sleep in 
patients suffering a MACCE). 
During S2 sleep, the LF/HF ratio was lower in patients with and without AHI 
≥20/hour (1.9 and 2.5 vs. 4.8; P = 0.008 and P = 0.03, respectively) as well as in 
those with and without MACCE (1.5 and 2.4 vs. 4.8; P = 0.01 and P = 0.02, 
respectively) despite that there were no significant differences in the LF and HF 
powers themselves. Patients with and without AHI ≥20/hour had lower normalised 
LF (58 nu and 60 nu vs. 75 nu; P = 0.02 and P = 0.03, respectively) and higher 
normalised HF (37 nu and 38 nu vs. 23 nu; P = 0.04 and P = 0.02, respectively) than 
controls. Patients with and without MACCE also had lower normalised LF (57 nu 
and 60 nu vs 75 nu; P = 0.02 and P = 0.03, respectively) and higher normalised HF 
(38 nu and 37 nu vs. 23 nu; P = 0.04 and P = 0.02, respectively). 
During REM sleep, LF was significantly lower in patients suffering a MACCE than 
in controls (192 ms2 vs. 417 ms2; P = 0.03). Patients with and without significant 
OSA (1.8 and 3.9 vs. 10.3; P = 0.04 and P = 0.001, respectively) had a remarkably 
lower LF/HF ratio as well as those not suffering a MACCE (2.5 vs. 10.3; P = 0.004). 
Patients with AHI ≥20/hour had lower normalised LF (62 nu vs. 82 nu; P = 0.002) 
and higher normalised HF than controls (35 nu vs. 17 nu; P = 0.003). The same was 
true in patients not suffering a MACCE in both normalised LF and normalised HF 
(66 nu vs 82 nu. and 31 nu vs. 17 nu, respectively; P = 0.009 for both). During S3-4 
sleep, there were no differences in the spectral parameters between the specified 
patient groups and controls. 
During evening wakefulness, the LF/HF ratio was significantly lower in patients 
with AHI ≥20/hour (2.0 vs. 5.3; P = 0.01). The patients with AHI ≥20/hour also had 
markedly lower normalised LF (63 nu vs. 81 nu; P = 0.005)  and  higher normalised  
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HF (33 nu vs. 18 nu; P = 0.006) than controls. The same was true in patients suffering 
a MACCE who also had significantly lower normalised LF (60 nu vs. 81 nu; P = 
0.003) and higher normalised HF (35 nu vs. 18 nu; P = 0.006).  
During morning wakefulness, the LF/HF ratio was only lower in patients with AHI 
≥20/hour (2.5 vs. 5.4; P = 0.03); these patients had decreased normalised LF (64 nu 
vs. 80 nu; P = 0.03) and increased normalised HF (32 nu vs. 20 nu; P = 0.04). In 
addition, total power (996 ms2 vs. 2174 ms2; P = 0.03), ULF power (69 ms2 vs. 223 
ms2; P = 0.02) and VLF power (580 ms2 vs. 1482 ms2; P = 0.02) were significantly 
lower in patients with AHI ≥20/hour; those who suffered a MACCE had decreased 
ULF (103 ms2 vs. 223 ms2; P = 0.03) and VLF (490 ms2 vs. 1482 ms2; P = 0.045) 
powers as well. 
5.6.2.3 Non-linear assessments 
In the DFA analyses, the fractal scaling exponent alpha 1 seemed to decrease both 
during sleep and wakefulness in all patients when compared to healthy controls. 
During evening wakefulness, the alpha 1 was significantly lower in patients with and 
without AHI ≥20/hour (1.11 and 1.16 vs. 1.37; P = 0.01 and P = 0.049, respectively). 
Those with and without MACCE also had lower alpha 1 (1.08 and 1.16 vs. 1.37; P 
= 0.01 and P = 0.04, respectively). In the morning, the alpha 1 was only lower in 
patients with AHI ≥20/hour (1.13 vs. 1.45; P = 0.002). In S2 sleep, patients with and 
without AHI ≥20/hour had lower alpha 1 (1.00 and 1.05 vs. 1.29; P = 0.01 and P = 
0.04, respectively) as well as those with and without MACCE (1.00 and 1.04 vs. 
1.29; P = 0.02 and P = 0.03, respectively). In REM sleep patients with AHI ≥20/hour 
had lower alpha 1 (1.06 vs. 1.43; P = 0.01) than controls as well as those not suffering 
a MACCE (1.10 vs. 1.43; P = 0.01). In S3-4 sleep, the alpha 1 did not differ 
significantly in any of the patient groups. Sample entropy differed only between 
sleep stages but was almost identical across the patient groups in a said sleep stage 
or during wakefulness. 
5.6.3 Association of HRV with OSA and MACCE 
5.6.3.1 Predictors of significant OSA and MACCE 
The covariance analyses showed that none of the HRV parameters in S2 sleep as 
well as either during evening or morning wakefulness was able to predict incident 
MACCE. Furthermore, no HRV parameter was predictive of significant OSA (AHI 
≥20/hour) during S2, S3-4 or REM sleep or evening wakefulness. In the morning, 
however, OSA with AHI ≥20/hour displayed lower fractal correlation of HRV as 
shown by the significantly lower alpha 1, compared to patients without such severe 
OSA (1.12 vs. 1.34; P = 0.02). This difference remained after adjusting for age, BMI, 
coronary artery disease and PAD history (P = 0.03). The unadjusted LF/HF ratio was 
also lower in patients with AHI ≥20/hour (2.5 vs. 3.9; P = 0.046) during morning 
wakefulness but the significance of this difference disappeared after the adjustments. 
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Patients with MACCE had lower maximum NNI (1018 ms vs. 1161 ms; P = 0.04), 
pNN50 (1.4 % vs. 2.7 %; p=0.04) and HF power (35 ms2 vs. 96 ms2; p=0.01) during 
REM sleep than those not suffering a major event. Of these, the difference in HF 
power remained significant after the adjustments (p=0.04). 
Patients suffering a MACCE had lower RMSSD (13 ms vs. 25 ms; p=0.009), HF 
power (25 ms2 vs. 162 ms2; p=0.004) and normalized HF units (33 nu vs. 52 nu; P = 
0.02) as well as higher LF/HF ratio (2.3 vs. 0.83; P = 0.04) and normalized LF units 
(65 nu vs. 46 nu; P = 0.02) during S3-4 sleep. Of these, the differences in RMSSD 
(P = 0.04), HF power (P = 0.03) and normalized HF units (P = 0.048) remained 
significant after the adjustments. 
ANCOVA was also performed from S2 sleep free from apnoea and arousals 
(available from 57 patients, 20 with AHI ≥20/hour and 14 suffering a MACCE). In 
this analysis, none of the HRV parameters predicted significant OSA or MACCE. 
5.6.3.2 HRV analyses with combined sleep stages 
In the analyses with all sleep stages combined, lower LF power (114 ms2 vs. 312 
ms2; P = 0.04) and lower HF power (68 ms2 vs. 150 ms2; P = 0.03) were associated 
with MACCE but these differences were not significant after the adjustments. The 
independent predictive value was most importantly affected by pre-existing coronary 
disease. 
When patients with worsening OSA (10-20/hour, 20-30/hour, >30/hour) were 
compared to those with AHI <10/hour, higher minimum NNI (891 ms vs. 767 ms; P 
= 0.008), maximum NNI (1198 ms vs. 1011 ms; P = 0.02) and mean NNI (1040 ms 
vs. 884 ms; P = 0.006) as well as standard deviation of NNI (47 ms vs. 25 ms; P = 
0.03) of the time domain parameters were associated with AHI 10-20/hour. In the 
frequency domain, higher VLF power (1435 ms2 vs. 312 ms2; P = 0.02), LF power 
(465 ms2 vs. 153 ms2; P = 0.04), HF power (249 ms2 vs. 69 ms2; P = 0.02) and total 
power (2080 ms2 vs. 615 ms2; P = 0.02) were predictive of AHI 10-20/hour. Patients 
with AHI ≥30/hour had higher NNI standard deviation (38 ms vs. 25 ms; P = 0.048) 
and higher RMSSD (31 ms vs. 21 ms; P = 0.02) as well as higher HF power (164 
ms2 vs. 69 ms2; P = 0.02) than those with AHI <10/hour. While these differences 
were observed after the adjustments, none of the HRV parameters was predictive of 
AHI 20-30/hour. VLF power was higher in patients with AHI 20-30/hour and 
≥30/hour but the increase in these groups was less than in those with AHI 10-20/hour 
and not statistically significant. Taken together, the HRV parameters did not change 
consistently in parallel with the AHI as OSA worsened. The HRV parameters in the 
analyses with combined sleep stages are detailed in table 5.   
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Table 5. HRV characteristics in combined sleep stages according to the severity of OSA and 
occurrence of MACCE. 
 AHI <10 
n = 18 
AHI 10-20 
n = 21 
AHI 20-30 
n = 14 
AHI ≥30 
n = 21 
No MACCE 
n = 52 
MACCE 
n = 22 
HR, 1/min 68 (59-78) 58† (50*-67†) 63 (55-72) 63 (52-74) 62 (53-72) 63 (55-73) 
NNI Min, ms 767 (124) 891 (126) † 830 (134) 810 (112) 828 (127) 824 (139) 
NNI Max, ms 1011 (195) 1198 (163) * 1085 (174) 1157 (252) 1129 (195) 1096 (245) 
NNI Mean, ms 884 (158) 1040 (141) † 958 (159) 960 (140) 970 (150) 950 (173) 
NNI Dev, ms 25 [16] 47 [24] * 32 [17] 38 [36] * 39 [30] 27 [28] 
NNI RMSSD, ms 21 [14] 31 [19] 21 [14] 31 [28] * 27 [22] 25 [23] 
NNI pNN50, % 2.0 [6.2] 6.5 [13.6] 1.1 [6.3] 5.9 [14.1] 4.7 [14.0] 4.2 [6.6] 
NNI SampEn 1.3 (0.3) 1.5 (0.2) 1.3 (0.3) 1.4 (0.3) 1.4 (0.3) 1.3 (0.3) 
NNIS Total, ms2 615 [1013] 2080 [2314] * 1245 [1737] 1119 [2603] 1435 [2687] 790 [1622] 
NNIS ULF, ms2 45 [138] 101 [232] 124 [210] 72 [65] 90 [185] 45 [77] 
NNIS VLF, ms2 312 [541] 1435 [1200] * 722 [883] 625 [1195] 763 [1221] 408 [1201] 
NNIS LF, ms2 153 [252] 465 [750] * 189 [366] 226 [785] 312 [774] 114 [275] ‡ 
NNIS HF, ms2 69 [71] 249 [378] * 63 [140] 164 [384] * 150 [318] 68 [142] ‡ 
NNIS LF/HF 2.9 [5.6] 2.5 [3.5] 3.3 [3.1] 1.4 [1.2] 2.3 [3.7] 2.1 [2.6] 
NNIS nLF, nu 62 (23) 60 (19) 65 (16) 53 (19) 60 (19) 59 (23) 
NNIS nHF, nu 35 (22) 38 (18) 31 (14) 42 (14) 38 (17) 36 (18) 
NNI Alpha 1 1.09 (0.33) 1.07 (0.29) 1.06 (0.35) 0.93 (0.30) 1.03 (0.29) 1.03 (0.39) 
Data are mean (standard deviation) or median [interquartile range] except for mean (range) for heart rate (HR). AHI 
= Apnea-hypopnea index, Alpha 1 = Fractal scaling exponent alpha 1, Dev = Standard deviation of NNI, HF = 
Power in the high frequency range (0.15-0.4 Hz), LF = Power in the low frequency range (0.04-0.15 Hz), MACCE 
= Major adverse cardiovascular and cerebrovascular event, ms = millisecond, nHF = normalized HF ratio, nLF = 
normalized LF ratio, NNI = normal-to-normal interval (i.e. time between normal beats in the electrocardiogram), 
NNIS = NNI spectrum, nu = normalised unit, pNN50 = Proportion of NNI >50 ms, RMSSD = Root mean square of 
the sum of successive differences (between adjacent normal-to-normal intervals, i.e. beat-to-beat variability), 
SampEn = Sample entropy, Total = Total power of the NNI spectrum, ULF = Power in the ultra-low frequency 
range (≤0.003 Hz), VLF = Power in the very low frequency range (0.003-0.04 Hz). One-way analysis of variance 
with Dunnett’s post hoc was used to test for differences between each OSA severity group (AHI 10-20/hour, 20-
30/hour and >30/hour) vs. AHI <10/hour. Analysis of covariance (ANCOVA) was used to test for independent 
differences between the OSA severity groups (same as above) and between patients with and without MACCE. The 
ANCOVA was adjusted for age, body mass index, presence of coronary artery disease and PAD duration (skewed 
variables log-transformed). *: p<0.05 compared to patients with AHI <10/hour; †: p<0.01 compared to patients with 
AHI <10/hour; ‡: p<0.05 between patients with and without MACCE (unadjusted analysis, no significant difference 
after adjustment). (Modified from original publication III) 
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6. DISCUSSION 
6.1 Prevalence of OSA in patients with PAD 
The prevalence of sleep apnoea is exceedingly high in patients with severe PAD 
requiring surgical intervention. In this study, sleep apnoea was mainly obstructive 
and unrelated to the common clinical signs (obesity or metabolic syndrome) or 
symptoms of the OSA syndrome (excessive sleepiness). Furthermore, OSA was 
more common in this study population than in most other previously studied patients 
with established risk factors or clinical manifestations of cardiovascular disease. A 
comparable prevalence (83 %) was reported in patients with drug-resistant 
hypertension (Logan et al. 2001). Since almost half of the subjects included by Logan 
et al. had co-morbidities predicting or indicating advanced cardiovascular disease, 
an overlap with the patients of this study is likely.   
Obesity is generally considered to be the major single risk factor for OSA. It has also 
been suggested that OSA is a manifestation of metabolic syndrome and has an 
incremental effect on the overall atherosclerotic burden (Vgontzas et al. 2005; 
Drager et al. 2010). However, most patients of the present study were not obese and 
earlier studies have also shown that obesity is not a characteristic clinical feature of 
PAD (Meijer et al. 1998). Although more than half of our patients in this study also 
had metabolic syndrome, neither its prevalence nor the patients´ waist circumference 
correlated to the severity of OSA; of the diagnostic criteria of metabolic syndrome, 
only decreased HDL was associated with OSA. Otherwise, the multivariate analysis 
failed to show any relation between the severity of OSA and common risk factors of 
atherosclerosis, including metabolic syndrome. Of the clinical manifestations of 
atherosclerosis, OSA was only associated with PAD.  Taken together, none of the 
co-morbidities or cardiovascular risk factors in this study explains the high 
prevalence of OSA.  
The proportion of central apnoea was remarkably high but the predominant type of 
apnoea was still obstructive even in patients with mild left ventricular dysfunction. 
Following our exclusion criteria, none of the patients had clinical heart failure and 
only four patients had mildly decreased LVEF. Nevertheless, decreasing LVEF was 
still an independent predictor of OSA even in this carefully selected population 
despite remaining mostly in the normal range.  This is in line with the earlier 
observations showing that OSA impairs left ventricular function (Laaban et al. 
2002). Mild left ventricular dysfunction is not supposed to cause central apnoea in 
the magnitude observed in this study (or vice versa). Accordingly, the clinical 
characteristics do not explain the high prevalence of sleep apnoea in this study, and 
simple mechanical airway obstruction without any concomitant or alternate 
aetiology is unlikely.  
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Mounting evidence shows that sleep apnoea enhances endothelial dysfunction and 
arterial stiffness which are the key factors in the development of atherosclerosis 
(Jelic et al. 2008; Drager et al. 2007; Herrington et al. 2004) and this has also been 
shown in minimally symptomatic patients (Kohler et al. 2008). Importantly, these 
common denominators of atherosclerosis and OSA can be alleviated with CPAP 
treatment (Ip et al. 2004; Drager et al. 2007), potentially reversing the progression 
of vascular damage. The severity of OSA is independently associated with early 
signs of atherosclerosis and has an additive effect with hypertension on these 
markers (Drager et al. 2005; Drager et al. 2009). Considering that OSA is closely 
related to both the precursors of atherosclerosis and clinical cardiovascular disease, 
the high prevalence of OSA in patients with severe systemic atherosclerosis that was 
shown in this study is not actually surprising. Taken together, OSA appears to be an 
important pathophysiological factor in the development of atherosclerosis and its 
progression to a severe stage.  
ABI values and toe pressures showed no association with the severity of OSA which 
speaks against a direct link between OSA and severity of PAD. This may be due to 
the fact that the patients included in this study already represent a severe form of 
PAD (requiring surgery); hence the Fontaine classification was not used. 
Furthermore, the anatomical extent of LEAD was not quantified. Therefore, except 
for the few patients presenting with critical ischaemia at baseline, there was little 
variation in terms of PAD severity. Studying a population with more diversity in this 
aspect (extent of LEAD, need and method of revascularisation, critical ischaemia), 
cardiovascular co-morbidities (atrial fibrillation, heart failure) or even more 
extensive vascular disease (e.g. renal or mesenterial atherosclerosis) could be 
informative. Indeed, the high prevalence of OSA has recently been replicated in 
patients with less severe PAD treated conservatively (Pizarro et al. 2015) and in 
patients undergoing PTA (Schahab et al. 2017) with an overall prevalence of 70 % 
and 81 %, respectively. Later studies have also shown an independent association of 
moderate-to-severe sleep apnoea with PAD in different ethnic groups (Shah et al. 
2015; Nagayoshi et al. 2016). Thus, OSA seems to become more common in parallel 
with worsening PAD (and vice versa). 
6.2 Possible alternate aetiologies of OSA in patients with PAD 
6.2.1 Role of central apnoea 
The fact that the apnoeic episodes were mixed with a remarkable central component 
raises the question whether central mechanisms are involved in the development of 
sleep-disordered breathing in PAD. Indeed, it has been shown that white matter 
disease of the brain is associated with the common risk factors and manifestations of 
atherosclerosis, including compromised lower limb circulation, and central sleep 
apnoea but there is no clear association with OSA (Davies et al. 2001; Longstreth et 
al. 2005; Robbins et al. 2005). However, white matter microstructural damage has 
been shown to correlate with the severity of OSA (Chen et al. 2015). Therefore, 
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asymptomatic ischaemic brain lesions may play a role in the disruption of central 
regulation of breathing during sleep in patients with severe PAD. This may account 
for the increased proportion of central apnoea episodes but does not explain the high 
prevalence of OSA per se. In addition, diabetes alone, via autonomic neuropathy, 
has been proposed to cause central apnoea by altering chemoreceptor gain and 
disturbing ventilatory control (Resnick et al. 2003). However, OSA is also more 
common in diabetic patients with autonomic neuropathy than in those without. This 
may be due to impaired sensory reflexes of the upper airway as well as decreased 
respiratory drive to the dilator muscles (Ficker et al. 1998). 
6.2.2 Bidirectionality between atherosclerosis and OSA 
6.2.2.1 Role of chemoreceptor feedback 
The presence of OSA seems to be tightly related to the severity of atherosclerosis. 
This suggests that the co-existence of these two conditions may not only be due to 
similar risk factors but may share a common pathophysiology instead. One 
speculative mechanism may be that advanced vascular disease affects the 
compensatory mechanisms that protect from airway collapse and obstruction. It can 
be further speculated that systemic atherosclerosis as reflected by PAD affects the 
afferent circulation of arterial chemoreceptors, causing increased sensitivity to 
hypoxia. The resulting hyperventilation and hypocapnia could potentially decrease 
ventilatory drive to muscles of the upper airway. The theoretical basis for this 
hypothesis is laid out below. 
Chronic hypoxia elicits increased sensitivity of the chemoreceptors and augmented 
ventilatory response in both animals and humans and may cause enlargement of the 
carotid body (Barnard et al. 1987; Bisgard 1994; Lahiri et al. 2000). Interestingly, 
nitric oxide has an inhibitory effect on carotid body function as it attenuates the 
chemoreceptor response to hypoxia (Prabhakar 1999). It is therefore plausible that a 
shortage of nitric oxide could be a potential underlying factor linking endothelial 
dysfunction, atherosclerosis, chemoreceptor dysfunction and respiratory 
dysregulation together. 
Early studies have observed hyperplasia of the carotid body and corresponding 
changes in ventilation in patients with hypertension and myocardial hypertrophy 
(Edwards et al. 1971; Smith et al. 1982; Trzebski et al. 1982). Animal studies have 
shown severe vascular damage in the afferent vessels of the carotid body that is 
related to hypertension (Smith et al. 1984; Bee et al. 1989). These changes, in turn, 
are associated with hyperventilation and hypocapnia although the carotid body 
hyperplasia may be present or absent (Barer et al. 1987; Bee et al. 1989; Heath & 
Smith 1992). Therefore, a hypothesis has been drawn that the overactivity of the 
chemoreceptors may be caused by reduced blood and oxygen supply to the carotid 
body due to vascular damage in the afferent arterioles, resulting in carotid body 
hyperplasia, respiratory changes and altered gas homeostasis (Bee et al. 1989; Barer 
1994). This would mean that hypertension precedes carotid body vascular damage 
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and causes chemoreceptor dysfunction even before the manifestation of 
atherosclerosis (Pfeiffer et al. 1984; Bee et al. 1989; Heath & Smith 1992). However, 
these findings have not been consistent in all studies with human subjects and some 
animal models have produced opposite results (Barer 1994), although the carotid 
body is enlarged in patients suffering from sustained hypoxia due to chronic lung 
disease (Edwards et al. 1971; Heath et al. 1982). In addition, the ventilatory response 
to hypoxia is physiologically blunted in continuous hypoxic conditions such as in 
high altitudes (Moore et al. 1986; Lahiri et al. 2000). Whether pathophysiological 
conditions such as severe atherosclerosis can mimic the effects of chronic hypoxia 
and cause chemoreceptor dysfunction is not known. 
6.2.2.2 Respiratory long-term facilitation 
Respiratory long-term facilitation (LTF) is a phenomenon in which intermittent 
hypoxia induces a progressive increase in respiratory drive that can be observed both 
in the motor output of the diaphragm and the upper airway dilator muscles. This 
stimulating effect may persist hours after the hypoxic events have subsided. LTF has 
been demonstrated in several animal models (Cao et al. 1992; Turner & Mitchell 
1997; Mateika & Fregosi 1997). During sleep and in human subjects, LTF has been 
shown to manifest as increased minute ventilation and attenuated flow limitation in 
snorers (Babcock & Badr 1998). A later study involving patients with moderate-to-
severe OSA treated with CPAP demonstrated reduced upper airway resistance in 
non-REM sleep during recovery from brief episodes of hypoxia but no change in 
minute ventilation (Aboubakr et al. 2001). It seems that LTF is mainly elicited in the 
enhanced action of upper airway dilators and when inspiratory flow limitation is 
present (Shkoukani et al. 2002; Babcock et al. 2003). Therefore, promotion of 
respiratory drive can be expressed both via increased ventilation efforts and 
preservation of upper airway patency but the latter seems to be more important. 
These compensation mechanisms can potentially prevent or alleviate OSA.  LTF also 
provides a feasible explanation for the fact that 80% of patients with OSA have 
extensive periods of uninterrupted sleep free of apnoea (Younes 2003). LTF is age-
dependent and its decline in animal models (Zabka et al. 2001; Zabka et al. 2003) is 
consistent with the way the prevalence of OSA behaves with age in humans (Bixler 
et al. 1998). Therefore, intermittent hypoxia should physiologically have a self-
limiting nature in healthy subjects and factors that impair the induction of LTF can 
potentially exacerbate OSA (Mahamed & Mitchell 2007) but there is no direct 
evidence of such a close relationship between LTF and OSA in humans. 
Carotid chemoreceptors are likely to play a role in the regulation of LTF. Intermittent 
hypoxia is required to trigger LTF, regardless of the severity of hypoxia (Mahamed 
& Mitchell 2007); sustained hypoxia does not work as such preconditioning (Baker 
& Mitchell 2000). Hypocapnia constrains LTF in rats (Olson et al. 2001) and in 
normal awake human subjects (Mateika et al. 2004). In humans during non-REM 
sleep, manifestation of LTF was observed when end-tidal CO2 was carefully 
monitored and maintained in the physiological window (Aboubakr et al. 2001; 
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Babcock et al. 2003) or in mild hypercapnia (Harris et al. 2006). Reduction of 
respiratory drive by hypocapnia promotes upper airway obstruction even after mild 
hyperventilation and without central apnoea (Onal et al. 1986; Badr & Kawak 1996; 
Badr et al. 1997) in subjects already predisposed to OSA such as snorers (Warner et 
al. 1987; Jordan et al. 2015). Therefore, it appears that a sufficient level of CO2 is 
needed to induce LTF. However, in OSA the increased response to disturbances in 
gas homeostasis may actually exacerbate apnoea (Charbonneau et al. 1994), 
suggesting that mechanisms that protect from airway obstruction are impaired.   
6.2.3 Evidence from OSA patients 
OSA induces adrenergic overdrive in metabolic syndrome via hypoxia-mediated 
chemoreceptor activation but sympathetic activation is increased also without OSA 
(Grassi et al. 2010). In addition, autonomic responses to chemoreceptor activation 
are potentiated in OSA (Narkiewicz et al. 1999) and altered chemoreflex function 
elicits sympathetic activation and hyperventilation (Kara et al. 2003). It can be 
speculated that circulatory changes in the chemoreceptors further disrupt the balance 
between oxygen and CO2 which is needed to maintain airway patency. This would 
mean that systemic vascular disease together with autonomic dysfunction and blood 
gas imbalance interact in such a way that atherosclerosis worsens OSA (and vice 
versa).  
A more recent study showed that incident new cardiovascular disease can indeed 
exacerbate OSA (Chami et al. 2011). Based on this study and some earlier 
observations, a reverse causality between sleep apnoea (both central and obstructive) 
and cardiovascular disease in the form of a vicious circle has been suggested (Man 
& Sin 2011). Proposed mechanisms include nocturnal fluid accumulation in the 
upper body in patients with heart failure (Yumino et al. 2010) and ventilatory 
instability due to low arousal threshold and an abrupt response to brief 
hypoventilation (Younes et al. 2001; Younes 2004; Younes 2008). The former 
mechanism is ruled out in this study since none of the patients had clinical heart 
failure. While the study by Chami et al. included patients suffering a myocardial 
infarction, both with or without heart failure, incident cardiovascular events 
promoted only worsening of OSA; they did not predict de novo OSA. 
Taken together, hyperventilation and chemical imbalance may be elicited by 
sympathetic activation when sustained hypoxia is sensed by the peripheral 
chemoreceptors which is deleterious when there is desynchronised coupling of 
chemical drive to upper airway dilators and respiratory pump muscles. Another 
plausible mechanism is that the function of central chemoreceptors is impaired due 
to cerebrovascular disease. However, our observational study design does not allow 
conclusions on causal relations. In addition, much of the evidence of these 
speculative mechanisms is derived from animal models with insufficient data from 
human subjects. Furthermore, two recent studies have questioned the concept that 
maintaining sufficient levels of CO2 is essential to restoring and preserving upper 
airway patency after apnoea (Cori et al. 2017; Cori et al. 2017). Therefore, the exact 
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pathophysiology of OSA in severe PAD remains obscure; it is likely that in severe 
atherosclerosis, several mechanisms are involved. Although OSA appears to be a 
characteristic feature in severe cardiovascular disease, it is unclear whether it starts 
to develop in the early stage of atherosclerosis along with endothelial dysfunction or 
in a later severe stage. 
6.3 Effect of OSA on the occurrence of MACCE 
The clinically most important finding in this study was that asymptomatic OSA is an 
independent predictor of major long-term cardiovascular and cerebrovascular events 
along with pre-existing coronary artery disease in patients with PAD undergoing 
vascular surgery. This is a novel finding in this patient group. According to our 
survival analysis, the impact of OSA on clinical outcome becomes significant in the 
first months following surgery and persists for up to five years. Age is likely to have 
an increasing effect on mortality after this point. While it is not surprising that 
coronary artery disease was common and associated with cardiovascular morbidity 
and mortality, the high prevalence of OSA and its association with MACCE provides 
an entirely new insight to the risk stratification of these patients. 
The fact that the major events were also associated with decreased HDL/Chol ratio 
is in line with previous data indicating that impaired lipid metabolism is a principal 
risk factor of cardiovascular morbidity and mortality. In this study, OSA was also 
linked to decreased HDL/Chol ratio. Intermittent hypoxia promotes sympathetic 
activation, oxidative stress, systemic inflammation and endothelial dysfunction 
(Kohler et al. 2008; Jelic et al. 2008); a latter randomised controlled trial showed a 
relationship between minimally symptomatic OSA and endothelial dysfunction that 
was reversible with CPAP treatment suggesting a direct causality (Kohler et al. 
2013). Therefore, OSA is associated with several common denominators that are 
also the key mechanisms in the pathophysiology of atherosclerosis. Furthermore, 
repeated apnoea per se may directly predispose to myocardial infarction through a 
variety of mechanisms such as reduced supply and increased demand of oxygen in 
the myocardium, systolic and diastolic dysfunction, and left ventricular hypertrophy 
(Bradley & Floras 2009). Accordingly, the current results further support the view 
that OSA has a close relationship with endothelial dysfunction and the 
pathophysiology of atherosclerosis. 
Troponin release indicating postoperative AMI was rare demonstrating that the 
included patients had a relatively low risk of cardiovascular complications compared 
to standard surgical PAD patients. This may be explained by the fact that our subjects 
were somewhat younger and healthier (e.g. lacking the most ill patients with 
congestive heart failure or end-stage renal disease). The protocol was especially 
strict in excluding patients with atrial fibrillation and all patients with pre-existing 
diagnosis of symptomatic OSA syndrome, further emphasising the importance of 
occult OSA. The absence of several established predictors of poor prognosis 
suggests that significant OSA in PAD patients needing surgical revascularisation has 
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a strong independent predictive value for long-term mortality and in an even greater 
extent if clinical coronary artery disease is present as well. However, there was no 
relation between OSA and perioperative and immediate postoperative AMI, possibly 
due to very few such events. Nonetheless, the five-year mortality was similar to that 
observed in the previous studies.  
CPAP may prevent adverse cardiovascular events in patients with severe OSA but 
decisive data from randomised controlled trials are lacking and obtaining such 
evidence (e.g. by using a sham CPAP control group) is challenging. Nonetheless, 
even asymptomatic patients may achieve risk reduction if CPAP is used for four 
hours per night or more (Peker et al. 2016; Abuzaid et al. 2017). Therefore, patients 
with PAD and OSA could benefit from optimal CPAP therapy. However, treatment 
adherence is doubtful in minimally symptomatic or asymptomatic OSA as compared 
to patients with EDS and the efficacy of CPAP treatment in surgical PAD patients 
with OSA has not been studied.  Based on the current data, no recommendations for 
screening and treatment of OSA in this population can be given. 
This study is in agreement with the concept that EDS is not relevant regarding the 
cardiovascular threat posed by OSA (Drager et al. 2010). On the other hand, a more 
aggressive pharmacologic secondary prevention even without CPAP treatment may 
be beneficial in this population. Furthermore, a simple and inexpensive screening 
method compared to complete overnight polysomnography should be established. 
The very close correlation of oxyhaemoglobin desaturation index with the AHI in 
this study supports the utilisation of overnight oximetry as the preferred means for 
screening. Since the threshold for significant OSA was set to AHI ≥20/hour, which 
means moderate or severe OSA, the risk for false positive findings with overnight 
oximetry is likely to be negligible. According to our current results, patients with 
coronary artery disease, a PAD history with a rapidly developing need for surgical 
treatment and impaired lipid metabolism may be a feasible group for screening and 
intervention in future research. 
6.4 Significance of heart rate dynamics 
6.4.1 Overview of the results from the HRV analyses 
The aim in assessing HRV in patients with OSA and PAD was to provide a more in-
depth understanding of the underlying pathophysiology. Impaired HRV is associated 
with autonomic dysfunction which is a common denominator of OSA and 
atherosclerosis as well as one of the key factors behind the adverse cardiovascular 
consequences of OSA. We hypothesised that if OSA turned out to be associated with 
impaired HRV, it could be the pivotal factor behind compromised cardiovascular 
adaptability in these patients. However, this was not the case since there were few 
HRV parameters bearing any correlation with significant OSA (AHI ≥20/hour). 
According to our results, measurement of HRV is not feasible for clinical risk 
stratification in these patients undergoing non-cardiac vascular surgery. This further 
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illustrates the importance of our other findings that relatively simple clinical 
parameters such as OSA, coronary artery disease and PAD history are superior in 
predicting long-term outcome in these high-risk patients.  
6.4.2 HRV alterations in patients with PAD 
Although decreased HRV is clearly detrimental in ischaemic heart disease, the 
association between HRV and PAD is more complex. Some earlier studies have 
shown that decreased HRV in patients with PAD has independent predictive value 
for cardiovascular complications and reflects autonomic neuropathy in patients with 
both PAD and type 2 diabetes mellitus (Mamode et al. 2001; Canani et al 2013). In 
this study, we observed decreasing LF power in patients with PAD compared to 
controls while the HF power increased to a lesser extent. One earlier study detected 
an increased LF/HF ratio in patients with PAD, whereas another study observed a 
trend towards a decreased LF/HF ratio and a favorable effect of exercise training on 
HRV (Goernig et al. 2008; Leicht et al. 2011). Despite demonstrating altered heart 
rate dynamics in patients with surgical PAD, the link of these findings with MACCE 
was very limited. Therefore, HRV is likely to be disturbed in the majority of these 
patients due to severe atherosclerosis, limiting the prognostic viability of HRV 
measurements. In other words, a single preoperative observation in any HRV 
parameter is very difficult to interpret (i.e. increased/decreased, normal/abnormal) 
and does not adequately serve as a means for clinical risk stratification. 
6.4.3 Effect of OSA on HRV 
OSA promotes sympathetic activation and corresponding alterations in spectral 
HRV analysis have previously been demonstrated in patients with OSA both during 
sleep and wakefulness (Narkiewicz et al. 1998; Dingli et al. 2003). One previous 
study showed the scaling exponent alpha 1 correlating closely with the AHI but this 
was not confirmed in another study (Penzel et al. 2003; da Silva et al. 2015). 
Furthermore, vagal control of heart rate during daytime is decreased in obese patients 
with OSA even before the onset of clinical cardiovascular disease (Balachandran et 
al. 2012). Interestingly, some earlier studies showed not only increased sympathetic 
activity in moderate OSA but also that this effect can be blunted in severe OSA with 
an impaired physiological increase during REM sleep (Gula et al. 2003; Kesek et al. 
2009).  
The minor alterations observed in heart rate dynamics in PAD patients were 
independently associated with MACCE in a handful of parameters and in patients 
with REM or S3-4 sleep available for analysis. Furthermore, these alterations did not 
clearly indicate breakdown of fractal heart rate dynamics related to OSA, i.e. the 
average scaling exponent values remained close to 1 or above (but less so during 
sleep). Alpha 1 was significantly lower in patients with AHI ≥20/hour during 
morning wakefulness than in those without such severe OSA, and this finding is 
reasonable as a consequence  of  potential disruption of neurocirculatory  regulation  
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due to sleep disturbed by apnoea. Thus, DFA measurements obtained from an 
individual patient provide limited information with respect to determining prognosis 
and guiding clinical decisions in the patients of this study. Although the alterations 
in heart rate dynamics in patients with severe PAD may to some extent be related to 
OSA, the increased risk conferred by OSA in this patient group is not explained by 
cardiac autonomic dysfunction alone. In addition, the prognostic viability of the 
observed differences that were associated with MACCE is further limited by the 
difficulty to obtain data from REM or S3-4 sleep for analysis.  
6.4.4 Interactions of PAD, OSA and HRV 
The LF/HF ratio has been perceived to reflect the sympathovagal balance, at least to 
some extent. When the LF/HF ratio increases under physiological conditions (e.g. 
exercise), the scaling exponent alpha 1 increases, indicative of an enhanced fractal 
correlation of heart rate (Tulppo et al. 2001). This self-similarity seems to be 
disrupted by persistent sympathetic activation, specifically when both the 
sympathetic and vagal branches (i.e. accentuated sympathovagal interaction) of the 
autonomic nervous system are activated, resulting in compromised cardiovascular 
adaptability (Tulppo et al. 2005). This kind of autonomic dysfunction is known to 
occur in heart failure and has been shown to be associated with increased mortality 
(Galinier et al. 2000). One could postulate that OSA with PAD could represent a 
similar pathophysiological condition, i.e. continuous parasympathetic compensation 
is required to counter sustained sympathetic activation. Predominance of 
sympathetic activation as reflected by increased LF/HF ratio during both REM and 
non-REM sleep has been shown in patients with OSA in an earlier study (Palma et 
al. 2013). In the patients of this study, the combined effect of frequent apnoea (both 
obstructive and central), arousals and intermittent hypoxia on the LF/HF ratio seems 
different. Since much of the HF power is related to sinus arrhythmia caused by 
breathing, this spectral component may especially be affected by OSA. In other 
words, HRV is affected by the rhythmicity of breathing events which may 
compromise the general feasibility of the analysis. Indeed, the use of the LF/HF ratio 
as a measure of cardiac sympathovagal balance has been questioned and must be 
interpreted with caution in general (Billman et al. 2013). Taken together, it seems 
that the use of the LF/HF ratio is not feasible in patients with OSA and severe PAD. 
This conclusion is also supported by the diversity of the behaviour of HRV in both 
PAD and OSA shown in previous studies.  
6.4.5 Predictive value of HRV alterations 
Widespread pathologic alterations in heart rate dynamics predictive of MACCE in 
patients with severe PAD were not found. Since the trend towards decreasing alpha 
1 during S2 sleep and wakefulness in patients suffering a MACCE was quite weak, 
it does not seem likely that clinically significant deterioration of fractal heart rate 
control would have become evident in a larger sample. However, alpha 1 was lower 
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in all patient subgroups than in controls, suggesting that autonomic control of HRV 
is altered in patients with PAD. Especially LF power was decreased consistently in 
all patient groups while the decreased HF power during REM and S3-4 sleep was an 
expectable finding and reflects impaired vagal compensation in patients suffering a 
MACCE. Because all of our patients had a severe form of PAD, it is feasible to 
suggest that their autonomic nervous system function, with or without OSA, is 
altered in such a way that potential differences are obscured. Conversely, it is also 
possible that due to our selection criteria and concomitant conservative treatment, 
the patients examined in this study had retained their autonomic adaptability to a 
certain degree. Another potential explanation to the lack of prognostic HRV 
alterations is that the effects of PAD, OSA and central apnoea may interact in such 
a way that interpretation of the HRV parameters becomes increasingly problematic. 
When HRV was analysed without sleep stage selection, independent alterations 
predictive of MACCE were not found. Instead, some significant findings with 
regards to the severity of OSA were observed. Patients with AHI 10-20/hour had 
remarkably higher power in most of the spectral parameters especially in the VLF 
band. However, the findings did not correlate with the worsening of OSA since the 
alterations in HRV were different or not significant as the AHI progressed. For 
example, a further increase in VLF power should have been expected (Gong et al. 
2016). In contrast with this earlier study, LF and HF power or their normalised units 
did not correlate consistently with the AHI. These results show that a dichotomic 
cut-off limit for the AHI cannot be used to assess the effect of OSA on HRV and 
accounting for the severity of OSA is not feasible when HRV is analysed in surgical 
PAD patients. It also seems that calculating nocturnal HRV generally during sleep 
is clinically feasible, rather than from selected sleep stages because the detrimental 
effects on autonomic function are not limited to the actual time of the apnoea but 
tend to persist over a longer period.    
6.5 Study limitations 
There are important limitations to be considered.  Due to strict exclusion criteria the 
study sample is relatively small and represents a subgroup of patients with PAD with 
a limited degree of co-morbidity. Approximately half of the screened patients were 
excluded and not evaluated for OSA or its symptoms which limits the viability of 
conclusions concerning the lack of sleepiness related to OSA. In addition, patients 
with a pre-existing diagnosis of OSA were excluded in order to avoid 
overrepresentation of symptomatic OSA syndrome and better determine the 
significance of occult asymptomatic or minimally symptomatic OSA in PAD. 
Therefore, the amount of asymptomatic OSA is probably disproportionate and the 
results cannot be directly extrapolated to the general clinical population of PAD 
patients.  On the other hand, if the oldest patients or those with heart failure or other 
co-morbidities were included, not only the prevalence of OSA but also the 
percentage of central apnoea would probably have been even higher. Caution must 
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therefore be taken in defining the type of apnoea (obstructive or central) or the 
phenotype of OSA in surgical PAD patients. 
A minor limitation is that systemic atherosclerosis was determined solely by the 
presence of LEAD; other forms of PAD (e.g. aortic, renal or mesenterial) were not 
evaluated. The presence of coronary or cerebrovascular disease was determined by 
clinical history; routine coronary angiography or carotid ultrasound were not 
performed. In addition, the threshold of AHI ≥20/hour that was used to determine 
significant OSA is somewhat arbitrary. However, it corresponds closely to the mean 
and median AHI observed in this study and was also based on risk calculations with 
subgroups. There was no continuous trend between the increase in the AHI and the 
risk of MACCE but this is consistent with an earlier large cohort study showing that 
cardiovascular risk does not parallel the AHI in a linear fashion (Shahar et al. 2001). 
Therefore, we feel that the cut-off level used in this study is appropriate. 
HRV could not be analysed in eleven patients, two of whom suffered a fatal MACCE 
during follow-up. Although the association of OSA with MACCE was also seen in 
the group of patients that underwent HRV analyses, the possibility still remains that 
existing HRV alterations associated with MACCE simply did not become evident in 
this particular group of patients (type II statistical error). Conversely, the statistical 
analysis of HRV did not control for mass significances; i.e. the sheer number of 
parameters and comparisons between patient groups in different sleep stages 
increases the likelihood of (false positive) chance findings. Furthermore, dividing 
the study population into four subgroups simultaneously accounting for significant 
OSA and MACCE (i.e. AHI<20/hour-MACCE, AHI<20/hour+MACCE, 
AHI≥20/hour-MACCE, AHI≥20/hour+MACCE) would have been optimal. Due to 
sample size and number of events, this was not possible. The small size of the 
subgroups in the analysis with 10/hour increments in the AHI, may have obscured 
potential effects of worsening OSA. In addition, non-stationarities in an HRV 
analysis are known to bias results toward sympathetic predominance and potentially 
obscure differences between groups (Magagnin et al. 2011). 
There was a mismatch in age and BMI between controls and patients. The control 
group was intended to consist of healthy volunteers without any cardiovascular 
disease or significant risk factors; thus, patients with moderate-to-severe OSA were 
excluded. The effect of mild OSA in controls may be negligible when compared to 
patients with or without AHI ≥20/hour. Nonetheless, the fact that the control group 
was unmatched and also had patients with OSA, limits the validity of conclusions 
based on these comparisons. 
6.6 Clinical implications and future considerations 
This study strengthens remarkably the role of OSA as an important 
pathophysiological factor in the development and progression of atherosclerosis. 
OSA is highly prevalent in severe PAD and has important prognostic significance. 
OSA  was  also  more  common   than  any  other  risk  factor  or   manifestation  of 
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atherosclerosis. These patients should be recognised as a high-risk group for 
cardiovascular complications. However, it is not clear whether OSA is a treatable 
cause of increased morbidity and mortality in PAD or merely a marker of severe 
atherosclerosis and autonomic dysfunction. The benefit of CPAP therapy in this 
patient group should be investigated and treatment should more frequently be 
considered for the patients that are symptomatic. 
OSA in this group is not caused by obesity but may share a common pathophysiology 
with PAD instead. Based on the absence of symptoms and the pronounced 
component of central apnoea, OSA associated with PAD appears to be an entirely 
different entity as opposed to OSA syndrome. While the theoretical basis of a 
bidirectional relationship between OSA and severe atherosclerosis makes sense, its 
scientific support is insufficient; therefore, the hypothesis of atherosclerosis as a 
potential cause of OSA remains speculative. The concept of any one-way or single-
factor causality is probably oversimplified; instead, a multi-factorial aetiology of 
OSA in these patients is likely. Understanding the underlying pathophysiology is 
important and further studies are warranted to establish the aetiology of OSA and 
meet the clinical needs stated above. 
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7. CONCLUSIONS 
The main results, according to the aims of the study, were as follows: 
 
1. OSA is exceedingly common in patients with PAD in need of surgical 
revascularisation and more than half of it is moderate or severe in difficulty. 
OSA is neither related to obesity or metabolic syndrome in this patient 
group, nor characterised by EDS. 
2. OSA is independently associated with postoperative major adverse events 
and poor long-term outcome following sub-inguinal vascular surgery due to 
severe PAD. The threshold for significant OSA to predict these events in this 
study was an AHI of ≥20/hour. 
3. HRV is significantly altered in patients with PAD undergoing sub-inguinal 
vascular surgery when compared to healthy controls but these alterations had 
very limited predictive value for postoperative major adverse events. 
Utilisation of HRV analyses for clinical risk stratification – even in specific 
sleep stages – in this patient group is not feasible. 
4. The influence of OSA on HRV in patients with PAD is not linearly related 
to the severity of OSA; HRV alterations did not explain the strong 
association of OSA with postoperative major adverse events.  
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